Discovery of the first small molecules targeting the mRNA binding protein IGF2BP2/IMP2 as potential target in cancer therapy by Abuhaliema, Ali M. H.




Discovery of the first small molecules targeting the mRNA 






zur Erlangung des Grades 
des Doktors der Naturwissenschaften 
der Naturwissenschaftlich-Technischen Fakultät 





























   
 
 












ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 I  
 
Contents 
Table of figures .......................................................................................................... VI 
Table of tables ......................................................................................................... VIII 
Appendix .................................................................................................................... IX 
Abbreviations .............................................................................................................. X 
Abstract .................................................................................................................. XVII 
Zusammenfassung ................................................................................................ XVIII 
Chapter I: IMP2 is a promising target in cancer therapy .......................................... XIX 
1 Introduction ............................................................................................................ 1 
1.1 Cancer incidence and mortality rates worldwide ............................................ 1 
1.1.1 Mode-of-action of chemotherapeutic agents ............................................ 2 
1.1.2 Potential chemotherapy side effects ........................................................ 3 
1.2 RNA-binding proteins as promising targets in cancer therapy ........................ 3 
1.2.1 Insulin like growth factor 2 mRNA binding proteins family ....................... 5 
 IMP2 role in cancer initiation and progression ...................................... 6 
 IMP2 signaling pathways ...................................................................... 8 
 Reported RNA target sequences of IMP ............................................... 9 
1.3 Biophysical methods used in drug discovery .................................................. 9 
1.3.1 Fluorescence polarization assay ............................................................ 10 
1.3.2 Differential screening fluorometry / thermal shift assay .......................... 11 
1.3.3 Microscale thermophoresis .................................................................... 12 
1.3.4 Saturation transfer difference - nuclear magnetic resonance ................. 13 
1.4 Aim of the present study............................................................................... 14 
2 Results ................................................................................................................. 15 
2.1.1 In vitro validation of IMP2 as a promising target in cancer therapy ........ 16 
2.1.2 Effect of IMP2 knockdown/knockout on cell viability and proliferation .... 16 
 IMP2 knockdown impact on cell proliferation ...................................... 16 
 IMP2 knockout impact on cell proliferation via MTT............................ 18 
Contents 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 II  
 
 IMP2 knockout impact on proliferation via ECIS ................................. 20 
2.1.3 Influence of IMP2 reduction on IMP1 and IMP3 expression .................. 21 
 Potential inter IMP interactions in colon cancer cells .......................... 21 
 Potential inter IMP interactions in liver cancer cells after IMP2 
knockout .......................................................................................................... 23 
 Potential inter IMP interactions in liver cancer cells after IMP2 
knockdown………………………………………………………………….………..24 
2.2 IMP2 isolation, characterization, and primary screening for inhibitors .......... 26 
2.2.1 Recombinant IMP2 isolation and characterization ................................. 26 
2.2.2 IMP2 amino acid sequence confirmation ............................................... 28 
2.2.3 FP primary screening ............................................................................. 29 
 Establishment of FP assay ................................................................. 29 
 FP-based primary screening ............................................................... 34 
 Pluronic® F-127 effect on FP assay findings ....................................... 34 
 Dose response studies of hit compounds ........................................... 35 
 Correlation of the half inhibitory concentration with competitive 
inhibitory constant ............................................................................................ 37 
2.3 Secondary confirmation of IMP2-hit compound interactions ........................ 38 
2.3.1 Confirmation of IMP2-hit compound interaction with thermal shift assay
 …………………………………………………………………………………38 
2.3.2 Confirmation of IMP2-hit compound interaction with microscale 
thermophoresis ................................................................................................... 39 
2.3.3 Confirmation and characterization of IMP2-hit compound interaction with 
STD–NMR ........................................................................................................... 41 
 Establishment and optimization of STD-NMR experiment .................. 41 
 Mode of interaction of compound # 4 with IMP2 ................................. 41 
 Overall summary of IMP2-hit compound mode-of-interaction ............. 42 
2.3.4 In silico confirmation and characterization of IMP2-hit compound 
interaction…………………………………………………………………………..…..44 
Contents 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 III  
 
 Molecular docking of compound # 4 in the RRM1 binding domains ... 45 
2.3.4.1.1 Compound # 4 and inhibition of IMP2-RNA (ACAC) complex ....... 45 
2.3.4.1.2 Compound # 4 and inhibition of IMP2-RNA (CGGA) complex ....... 45 
2.4 Biological activity assessment of final hit compounds (potency, specificity, 
and safety) ................................................................................................... 47 
2.4.1 Biological activity of final hit compounds ................................................ 47 
 IMP2 expression in different cancer cell lines ..................................... 47 
 Effect of hit compounds on cancer cell viability .................................. 48 
 Assessment of hit compound on-target activity via MTT ..................... 49 
 2.4.1.3 Assessment of hit compound on-target activity via ECIS ........ 50 
2.4.2 Cytotoxicity of hit compounds on human cells ....................................... 52 
 Effect of hit compounds on HUVEC cells ............................................ 52 
 Cytotoxicity of hit compounds on differentiated Huh7 cells ................. 53 
 Influence of Huh7/7.5 cells differentiation on IMP expressions ........... 54 
2.4.2.3.1 Impact of HS differentiation on IMP RNA levels ............................ 54 
2.4.2.3.2 Impact of HS differentiation on IMP protein levels ......................... 56 
2.4.3 In vivo biological activity of hit compounds............................................. 57 
3 Discussion ............................................................................................................ 58 
Chapter II: Methodology ............................................................................................ 63 
4 Chemicals and reagents ....................................................................................... 64 
5 Methods ............................................................................................................... 64 
5.1 Cell culture ................................................................................................... 64 
5.2 IMP2 siRNA knockdown ............................................................................... 64 
5.3 IMP2 CRISPR mediated knockout ............................................................... 65 
5.4 Western blot ................................................................................................. 66 
5.4.1 SDS-polyacrylamide gel electrophoresis ............................................... 66 
5.4.2 Blotting ................................................................................................... 66 
5.4.3 Near infrared immunodetection .............................................................. 67 
Contents 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 IV  
 
5.5 Cytotoxicity and anti-proliferative measurement ........................................... 68 
5.6 Gene expression analysis ............................................................................ 68 
5.7 Bacterial culture ........................................................................................... 70 
5.7.1 Generation to competent cells ............................................................... 70 
5.7.2 Plasmid transformation .......................................................................... 70 
5.7.3 Plasmid isolation .................................................................................... 71 
5.8 Protein purification ....................................................................................... 71 
5.8.1 IMP2 expression .................................................................................... 71 
5.8.2 Immobilized metal affinity chromatography ............................................ 71 
5.8.3 Recombinant IMP2 visualization ............................................................ 72 
5.8.4 RNA electrophoresis .............................................................................. 72 
5.8.5 Liquid chromatography – tandem mass spectrometry ........................... 73 
5.9 Fluorescence polarization-based screening assay ....................................... 73 
5.9.1 Probe design .......................................................................................... 73 
5.9.2 Compound libraries ................................................................................ 74 
5.9.3 FP assay optimization and validation ..................................................... 74 
5.9.4 FP-based screening ............................................................................... 75 
5.9.5 FP-based dose-response measurement ................................................ 76 
 Compound solubility test ..................................................................... 76 
5.10 Thermal shift assay ................................................................................... 76 
5.11 Microscale thermophoresis technique ....................................................... 76 
5.12 Saturation transfer difference – NMR ........................................................ 77 
5.13 Molecular docking ..................................................................................... 78 
5.14 Biological activity of hit compounds on cell viability and proliferation ........ 78 
5.15 Electric cell-substrate impedance sensing ................................................ 78 
5.16 Proliferation of primary human umbilical vein endothelial cell ................... 79 
5.17 Differentiation of Huh7 cells ...................................................................... 79 
5.18 In vivo xenograft zebrafish embryo model ................................................. 79 
Contents 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 V  
 
5.19 Statistics .................................................................................................... 80 
Summary and conclusion .......................................................................................... 81 
supplementary data ................................................................................................... 82 
References ................................................................................................................ 88 
Publications ............................................................................................................... 99 














Table of figures 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 VI  
 
Table of figures 
Figure 1: Estimated number of the newly diagnosed cancer cases and deaths .......... 1 
Figure 2: Chemotherapeutic agents and their mode-of-action ..................................... 2 
Figure 3 : RBPs role in the post-transcriptional regulation ........................................... 4 
Figure 4: IMP’s amino acid sequence and binding domains ........................................ 5 
Figure 5 : Structure of IMP2 and its variant p62 .......................................................... 6 
Figure 6: Association of IMP2 expression with survival rate ........................................ 7 
Figure 7: Descriptive sketch of IMP2 regulation network ............................................. 8 
Figure 8 : Concept of fluorescence polarization assay  ............................................. 10 
Figure 9 : Principle of thermal shift assay. ................................................................. 11 
Figure 10: Principle of microscale thermophoresis technique .................................... 12 
Figure 11 : Principle of STD-NMR in characterization of binding mode ..................... 13 
Figure 12: Hypothesis to be tested ............................................................................ 14 
Figure 13 : Impact of IMP2 knockdown on cell viability ............................................. 17 
Figure 14 : Impact of IMP2 knockout on cell viability ................................................. 19 
Figure 15 : Effect of IMP2 knockout on cell proliferation ............................................ 20 
Figure 16 :Impact of IMP2 knockout on IMP1 and IMP3 expression in colon cancer 
cells  .......................................................................................................................... 22 
Figure 17: Impact of IMP2 knockout on IMP1 and IMP3 expression in liver cancer 
cells ........................................................................................................................... 23 
Figure 18 : Impact of IMP2 knockdown on IMP1 and IMP3 expression in liver cancer 
cells ........................................................................................................................... 25 
Figure 19 : Isolation and characterization of recombinant IMP2 protein .................... 27 
Figure 20 : IMP2 amino acid sequence confirmation ................................................. 28 
Figure 21 : Fluorescence polarization assay development and optimization ............. 30 
Figure 22 : The robustness of FP assay .................................................................... 31 
Figure 23 : Characterization of IMP1 lead compound interaction with IMP2 RNAs ... 32 
Figure 24 : Characterization of IMP2 functional binding to different RNA targets by FP 
assay ......................................................................................................................... 33 
Figure 25 : FP primary screening and characterization of hit compounds ................. 34 
Figure 26 : Effect of Pluronic® on FP assay findings ................................................. 35 
Figure 27 : FP primary screening and characterization of hit compounds ................. 36 
Figure 28 : Chemical classification and IC50s of hit compounds ................................ 36 
Figure 29 : Thermal shift assay confirmation of hit compounds ................................. 38 
Table of figures 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 VII  
 
Figure 30: Comparison of IC50 values for compound # 9 with MST and FP assays .. 40 
Figure 31 : Interaction mode of compound # 4 predicted by STD-NMR .................... 42 
Figure 32 : Colored epitopes of hit compounds based on STD-NMR data ................ 43 
Figure 33 : Homology models for the molecular docking studies ............................... 44 
Figure 34 : Molecular docking of compound # 4 in IMP2 binding domains ................ 46 
Figure 35 : IMP2/p62 expression in different cancer cell lines ................................... 47 
Figure 36 : Biological activity of final screening hits ................................................... 48 
Figure 37 : Target specificity of hit compounds ......................................................... 49 
Figure 38 : Impact of hit compounds on cell proliferation in the absence of IMP2 ..... 51 
Figure 39 : Effect of hit compounds on HUVEC cells. ............................................... 52 
Figure 40 : Effect of hit compounds on differentiated Huh7 cells ............................... 53 
Figure 41: Influence of Huh7.5 differentiation on IMPs expression ............................ 55 
Figure 42 : Influence of Huh7 differentiation on IMPs expression .............................. 56 
Table of tables 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 VIII  
 
Table of tables 
Table 1: Reported RNA target sequences of IMP ........................................................ 9 
Table 2 : Summary of probe sequences used in FP assay validation ....................... 29 
Table 3: Summary of Ki values of hit compounds. .................................................. 37 
Table 4:  siRNA oligonucleotide used in IMP2 knockdown. ....................................... 65 
Table 5: Antibody dilutions used for immunodetection. ............................................. 67 























ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  





Table 1. Descriptive data of class A .......................................................................... 82 
Table 2. Descriptive data of class B .......................................................................... 83 
 
Supplementary figures  
Figure 1. STD-NMR IMP2 complex analysis ............................................................. 84 
Figure 2. DMSO concentration vs mean cell viability ................................................. 85 
Figure 3. DMSO concentration vs median cell viability .............................................. 86 












ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ  




∆Tm melting temperature shift 
°C grad Celsius 
µM micro molar 
13C NMR carbon NMR 
1H proton spectrum 
1H NMR proton NMR 
2-ME 2-mercaptoethanol 
aa amino acid 
ANOVA analysis of variance 
ARE AU rich element 
AU adenylate-uridylate 
BSA bovine serum albumin 
CaCl2 calcium chloride 
cDNA complementary DNA 
CDS circular dichroism spectroscopy 
Co control 
CO2 carbon dioxide 
CRISPR/Cas9 
clustered regularly interspaced short palindromic 
repeats / associated cas9 protein. 
d doublet peak 
D2O deteriorated water 
DEPC diethyl pyrocarbonate 
DMEM Dulbecco’s Modified Eagle’s Medium 
Abbreviations 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 XI  
 
DMSO dimethyl sulfoxide 
DMSO D6 deteriorated DMSO 
DNA deoxyribonucleic acid 
dpi diploid 
DTT dithiothreitol 
E. coli Escherichia coli 
EC50 half maximal effective concentration 
ECIS electric cell-substrate impedance sensing 
eCLIP enhanced crosslinking and immunoprecipitation 
EDTA ethylene diamine tetra acetic acid 
ELAVL1 embryonic lethal abnormal vision Drosophila like 1 
EMSA electrophoretic mobility shift assay 
FCS fetal calf serum 
FDA American Food and Drug Administration 
FI fluorescence intensity 
FLC fluorescein 
FP fluorescence polarization 
FPcomp FP competition assay 
FPKM fragments per kilo base per million mapped reads 
FPsat FP saturation assay 
FRET fluorescence resonance energy transfer 
GBC gallbladder carcinoma 
h hour 
HC high control 
Abbreviations 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 XII  
 
HCC hepatocellular carcinoma 
HCT116 human colon cancer cell line 
HCV hepatitis C virus 
Hep3B human liver cancer cell line 
HepG2 human liver cancer cell line 
HIPS 
Helmholtz Institute for Pharmaceutical Research 
Saarland 
His histidine 
HMGA2 high-mobility group AT-hook 2 
hnRNPLL heterogeneous nuclear ribonucleoprotein L-like  
HPLC high performance liquid chromatography 
HS human serum 
HSQC heteronuclear single quantum correlation 
Huh7 human liver cancer cell line 
HuR human antigen R 
HUVEC human umbilical vein endothelial cell 
I0 
intensity of one signal in the off-resonance or 
reference spectrum 
IC50 half maximal inhibitory concentration 
IGF2 insulin-like growth factor 2 
IGF2BP1-3/IMP1-3 insulin-like growth factor 2 mRNA binding proteins 1-3 
IgG immunoglobulin G 
IMAC immobilized metal affinity chromatography 
IPTG isopropyl-β-d-thiogalactopyranosid 
Isat intensity of a signal in the on-resonance spectrum 
Abbreviations 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 XIII  
 
J coupling constant 
kb kilo base 
KCl potassium chloride 
KD constant of dissociation 
kD kilo Dalton 
KH K homology 
LC low control 
LC-MS/MS liquid chromatography - tandem mass spectrometry 
m multiple peak 
MCF7 human breast cancer cell line 
mg mile gram 
MgCl2 magnesium sulphate 
MgCl2 magnesium chloride 
MgSo4 Magnesium sulfate 
ml mile liter 
mM mile molar 
MOPS 3-(N-morpholino) propane sulfonic acid 
mP mile polarization 
mp melting point 
mRNA messenger RNA 
MST microscale thermophoresis 





ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 XIV  
 
MW molecular weight 
MWCO molecular weight cut-off 
NaCl sodium chloride 
NF-κB 
nuclear factor 'kappa-light-chain-enhancer' of 
activated b-cells 
ng nano gram 
nM nano molar 
NMR nuclear magnetic resonance 
NS5A nonstructural protein 5A 
ON overnight 
P value probability value 
p62 splice variant of IMP2 
PAR-CLIP 
photoactivatable ribonucleotide – enhanced 
crosslinking and immunoprecipitation 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pET-28a bacterial expression vector in E. coli 
pH potential hydrogen 
ppm parts per million 
PqsD Pseudomonas quinolone signal biosynthetic enzyme 
q quartet peak 
RAC1 Ras-related C3 botulinum toxin substrate 1 
RBP RNA binding protein 
RNA ribonucleic acid 
RNAP RNA-polymerase enzyme 
Abbreviations 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 XV  
 
RNase ribonuclease 
ROS reactive oxygen species 
RPMI Roswell Park Memorial Institute Medium 
RRM RNA recognition motif 
RT room temperature 
RT-qPCR real-time quantitative polymerase chain reaction 
s singlet peak 
Sat saturation 
SD standard deviation 
SDS-PAGE 
sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SELEX 
systematic evolution of ligands by exponential 
enrichment 
SEM standard deviation of the mean 
siRNA small interfering RNA 
STD saturation transfer difference 
SW480 human colon cancer cell line 
t triplet peak 
Tm melting temperature 
tR retention time  
Tris-HCl (hydroxymethyl)aminomethane-hydrochloride 
TSA thermal shift assay 
UCP1 uncoupling protein 1 
UV ultraviolet 
WB Western blot 
Abbreviations 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 XVI  
 
WHO World Health Organization 
Z’ robustness value 
ZBP1 zipcode binding protein 1 
 
Abstract 
ــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  




The mRNA binding protein IGF2BP2/IMP2 is overexpressed in several cancer types, 
promotes tumorigenesis and tumor progression, and has been suggested to worsen 
disease outcome. Therefore, inhibition of IMP2 represents a promising approach in 
cancer therapy.  
The hypothesis to be tested within this thesis was (I) validate the target, (II) set up a 
screening assay for small molecule inhibitors of IMP2, and (III) test the biological 
activity of the obtained hits in vitro and in vivo. 
In vitro target validation using IMP2 siRNA knockdown and CRISPR/Cas9-mediated 
IMP2 inactivation showed a reduction in cell viability and proliferation, compared to 
control cells as determined by MTT assay, and electric cell-substrate impedance 
sensing (ECIS). 
Different compound libraries were screened for IMP2 inhibitors using a fluorescence 
polarization assay, and results were confirmed by thermal shift assay, microscale 
thermophoresis and saturation transfer difference - NMR. 
 The biological activity of hit compounds was tested in cells expressing different IMP2 
levels and confirmed specificity for cells expressing high levels of the target. Hit 
compounds significantly reduced tumor growth in vivo.  
In conclusion, our findings support that IMP2 represents a druggable target to reduce 
tumor cell proliferation. The identified hits provide a basis for subsequent lead 
generation efforts. 
Zusammenfassung 
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Das mRNA-bindende Protein IGF2BP2/IMP2 wird bei verschiedenen 
Krebserkrankungen überexprimiert. IMP2 fördert sowohl die Entstehung von Tumoren, 
als auch deren Progression, sodass es mit einer schlechten Krankheitsprognose in 
Verbindung gebracht wird. Daher stellt die Hemmung dieses Proteins einen 
vielversprechenden Ansatz in der Krebstherapie dar.  
Die im Rahmen dieser Arbeit zu testende Hypothese bestand darin, (I) das IMP2 als 
Ziel zu validieren, (II) robuste Testverfahren für niedermolekulare IMP2-Inhibitoren zu 
etablieren und (III) die biologische Aktivität der erhaltenen Trefferverbindungen in vitro 
und in vivo zu testen. 
Um IMP2 in vitro als Ziel validieren zu können, wurde dieses einerseits unter 
Verwendung von siRNA herunterreguliert und andererseits mittels CRISPR/Cas9 
inaktiviert. Dabei konnte Sowohl im MTT-Test, als auch mit dem Verfahren der 
elektrischen Zellsubstrat-Impedanzmessung (ECIS) eine Verringerung der 
Lebensfähigkeit und Proliferation von Krebszellen im Vergleich zu Kontrollzellen 
gezeigt werden.  
Fluoreszenzpolarisationsassays wurden benutzt, um verschiedene 
Substanzbibliotheken auf IMP2-Inhibitoren zu durchsuchen. Positive Ergebnisse 
konnten unter Verwendung der folgenden Verfahren bestätigt werden: Thermische 
Verschiebung Assay, Mikroskalige Thermophorese und Sättigungs-Transfer-Differenz 
- NMR bestätigt.  
Die biologische Aktivität der Trefferverbindungen wurde in Zellen getestet, die 
unterschiedliche IMP2 – Spiegel exprimierten; in Zellen mit hoher IMP2-Expression 
konnte dadurch ebenfalls die Spezifität dieser Verbindungen untermauert werden. Des 
Weiteren reduzierten die Trefferverbindungen  das Tumorwachstum in vivo signifikant.  
Zusammenfassend zeigen unsere Ergebnisse, dass IMP2 als therapeutisches Ziel die 
Tumorzellproliferation reduzieren kann. Dabei bilden die identifizierten 
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Chapter I: IMP2 is a promising target in cancer therapy 
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1 Introduction  
1.1 Cancer incidence and mortality rates worldwide 
Cancer is a global health burden, it ranks the first or second most leading cause of 
death in more than 90 countries worldwide (Bray et al., 2018). In 2018, more than 
eighteen million cases were newly diagnosed with different types of cancer worldwide 
(Figure 1 Bray et al., 2018). In 2040, according to the World Health Organization 
(WHO) estimates, the number of yearly diagnosed cancer cases will be increased by 
2 folds (World Health Organization, 2020). Cancer incidence rate is increased 
progressively regardless to the demographic factors (Bray et al., 2018).  
 
Figure 1: Estimated number of the newly diagnosed cancer cases and deaths in 2018 from both gender 
at all ages. Figure was adapted from Bray et al. (2018).    
According to WHO statistics, the number of cancer deaths in 2018 exceeded nine 
millions worldwide (Figure 1 Bray et al., 2018). One out of six death cases is caused 
by one of cancer types (World Health Organization, 2020). In 2008, the overall 
economic impact of death and disability caused by cancer was $895 billion worldwide 
(Armer et al., 2013). Adopting new policies by global health organizations for fighting 
against cancer burden will save millions of human lives, as well billions of dollars. 
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1.1.1 Mode-of-action of chemotherapeutic agents 
Chemotherapy uses one or more chemotherapeutic agents as part of an identical 
chemotherapy regimen. Chemotherapeutic agents exert their actions in different 
mechanisms (Figure 2 Hoffman et al., 2012), some of them targeting specifically the 
cycling cells and others act on cycling and resting cells (cycling cells more sensitive) 
(Alimbetov et al., 2018; Mills et al., 2018). 
 
Figure 2: Chemotherapeutic agents and their mode-of-action. Figure was adapted from (Hoffman et al., 
2012). 
Folic acid analogues interfere with DNA and RNA synthesis by inhibiting their precursor 
products (Hagner and Joerger, 2010).  Anthracycline antibiotics intercalate into DNA 
and inhibit its replication, and ergot alkaloids restricts the microtubules functions and 
inhibit formation of mitotic spindles (Booser and Hortobagyi, 1994). Alkylating agents 
lead to addition of an alkyl group to the guanine base of the DNA molecule, prevent 
double strand cross linkage, and induce breakage of the DNA strands (Ralhan and 
Kaur, 2007). Topoisomerase inhibitors as topotecan interfere with DNA transcription 
and replication by inhibition of the topoisomerase I and II enzymes. Topoisomerase 
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enzymes control the 3D structures of DNA via interfering of the phosphodiester 
backbone of DNA (Jain et al., 2017; Pommier, 2013). 
Chemotherapy based on cancer type in the early stages could be curative and prevent 
cancer relapse (Berger, 1986). In moderate to advanced stages, chemotherapy could 
increase the survival time from months to few years based on cancer type and its 
sensitivity to chemotherapy (Neugut and Prigerson, 2017). In advanced and late 
stages, palliative chemotherapy is used to relive symptoms, and improve the quality of 
life of the cancer patients (Neugut and Prigerson, 2017). 
1.1.2 Potential chemotherapy side effects 
Beside the desired biological activity of chemotherapeutic agents, they have also 
serious side effects. Most of chemotherapeutic agents lack the specificity and affecting 
the normal cells beside the cancerous cells (Pearce et al., 2017).  
The side effects of chemotherapy range could be mild as nausea, vomiting, and skin 
sensitivity. Weight loss and hair loss are reported with most of the chemotherapeutic 
agents (Nurgali et al., 2018; Pearce et al., 2017). 
Cardiotoxicity is a serious adverse effect caused by certain commonly used 
chemotherapeutic agents as doxorubicin, leading to increase in morbidity and mortality 
rates (Volkova and Russell, 2011). Chemo brain is a reported neurological side effect 
of chemotherapy concerning to foggy thinking, memory problems, and anxiety 
(Kovalchuk and Kolb, 2017). 
Furthermore, serious drug-drug interactions were reported with a wide range of 
commonly used chemotherapeutic agents that limit their uses (Monteiro et al., 2019). 
1.2 RNA-binding proteins role in cell biology 
RNA-binding proteins (RBPs) are proteins that interact with RNA and make complex 
over one or multiple RNA-binding domains (Hentze et al., 2018). Binding of these 
proteins to RNA modify the fate and / or function of targeted RNAs (Idler and Yan, 
2012). Numerous RBPs have been discovered and investigated, they play an 
important role in diverse physiological functions. They are involved in mRNA maturity, 
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stability, localization, and translation of mRNA targets (Figure 3 Glisovic et al., 2008). 
Several RBPs as hnRNPLL are splicing factors involved in exons recognition (Ergun 
et al., 2013). RBPs interact with several miRNAs and regulate their biogenesis and 
function (Newman et al., 2008; Taylor et al., 2013). Furthermore, RBPs play a role in 
the immune system responses by modulating the development and activation of B and 
T cells (Alkhatib et al., 2012; DeMicco et al., 2015). 
 
Figure 3 : RBPs role in the post-transcriptional regulation. Figure was adapted from Zhou et al. (2015). 
RBPs are overexpressed in several diseases particularly in cancer, they serve as 











ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 5  
 
1.2.1 Insulin like growth factor 2 mRNA binding proteins family 
Insulin like growth factor 2 mRNA binding proteins (IGF2BPs/IMPs/VICKZs) are belong 
to RBPs, they bind to IGF2 RNA and other several targets RNAs and control their 
expression, translocation, maturity and translation (Cao et al., 2018). IMPs have high 
structure and function similarity (Figure 4 Degrauwe et al., 2016). They have two RNA 
recognition motifs (RRM1-2) in the N- terminal and four KH homology domains (KH1-
4) in the C-terminal (Nielsen et al., 1999). In vitro investigations have revealed that the 
KH binding domains are responsible for RNA binding (Amarasinghe et al., 2001; Farina 
et al., 2003; Nielsen et al., 2002). In addition, RRMs motifs play an essential role in the 
stability of IMP2-RNA complexes and regulate the interactions between IMP2-RNA 
complex and other RBPs (Bell et al., 2013; Nielsen et al., 2004). The linker region 
between RRM2 and KH1 mediates the interaction with mTOR mRNA by 
heterodimerization of IMP1 and IMP3, or homodimerization of IMP2 (Dai et al., 2013; 
Dai et al., 2011).  
Figure 4: IMP’s amino acid sequence and binding domains. (A) Alignment of IMPs amino acid sequence 
represent conserved similarity in RNA binding domains. (B) Schematic presentation of IMP RNA binding 
domains. Figure was adapted from Degrauwe et al. (2016). 
IMPs are expressed extensively during fetal development and maturation in different 
tissues. IMP expression decreases in most tissues after birth (Czepukojc et al., 2019; 
Degrauwe et al., 2016). Overexpression of IMPs has been reported in several diseases 
as diabetes mellites, neural disorder, heart diseases and cancer. Expression of IMPs 
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in adult tissues has been described to be oncogenic in different types of tumors, 
including hepatocellular carcinoma (HCC), colon, and lung cancer (Dimitriadis et al., 
2007; Kessler et al., 2016). IMPs regulate the mRNAs of several oncogenes that are 
involved in cancer initiation and progression, leading to aggressive tumors (Degrauwe 
et al., 2016). 
 IMP2 role in cancer initiation and progression 
IMP2 gene is located on chromosome 3 locus 3q27.2 and contains 16 exons 
(Christiansen et al., 2009), encodes a 66.1 kDa IMP2 protein (Nielsen et al., 1999). 
IMP2 has six variants, p62 is a splicing variant lacks exon 10 encoding a 62 kDa IMP2 
isoform (Figure 5 Cao et al., 2018). p62 has a 43 amino acids loss between KH23 
binding domains (Cao et al., 2018). 
Figure 5 : Structure of IMP2 and its variant p62. Figure was adapted from Cao et al. (2018).  
IMP2 protein has a distinct role in cancer progression and responsiveness to 
chemotherapy (Kessler et al., 2017). IMP2 was highly expressed in different cancers 
compared to IMP1 and IMP3 (Dai et al., 2017; Kessler et al., 2017). The expression 
and translation of different oncogenes is controlled directly or indirectly by IMP2. IMP2 
oncogenes interaction increases cellular proliferation, growth rate, cell migration (Cao 
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et al., 2018). Furthermore, the metabolic activity and energy expenditure were 
improved after IMP2 was knocked out, lake of IMP2 reduces the development of fatty 
liver diseases and malignancy (Dai et al., 2015). IMP2 and its variant p62 are involved 
in elevation of RAC1 expression and generation of reactive oxygen species (Kessler 
et al., 2015). Furthermore, IMP2 knockdown in adherent Glioblastoma cells decreases 
their oxygen consumption rate and inhibit glycolysis (Janiszewska et al., 2012).  
P62 transgenic mice model reflected higher rates of tumor initiation and progression 
compared to the wild type. Also, IMP2 knockout mice model showed reduction in size, 
total weight, and linear growth compared to the wide type (Kessler et al., 2015).  
The correlation of IMP2/p62 overexpression with survival rate among cancer patients 
was investigated using Kaplan-Meier analysis. Results showed that the survival rate is 
significantly reduced with IMP2/p62 overexpression (Figure 6; Alajez et al., 2012; 
Barghash et al., 2016; Dahlem et al., 2019; Davidson et al., 2014; Kessler et al., 2015; 
Zhang et al., 2011). 
 
Figure 6: Association of IMP2 expression with survival rate. Based on the fragments per kilo base per 
million mapped read (FPKM) values of IMP2 expression, patients were classified into high and low 
expression groups. Blue represents low IMP2 expression and red represents high IMP2 expression. 
Association between IMP2 expression and patient survival rate was examined using Kaplan-Meier 
analysis. Figure was adapted from the Human Protein Atlas; available from www.proteinatlas.org (Uhlen 
et al., 2017).  
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 IMP2 signaling pathways  
All IMPs are reported to interact with IGF2 RNA, but each IMP protein displays a unique 
RNA interaction properties and interact with variable targets (Bell et al., 2013). Several 
studies have been reported that high mobility group proteins 2 (HMGA2) in assistance 
of nuclear factor κB (NF-κB) binds to the AT-rich region of the first intron of IMP2 gene 
and promote its transcription (Cleynen et al., 2007; Henriksen et al., 2010). This 
enhance cancer cells proliferation and increase their growth rate.  
                                                                                                                                                                
Figure 7: Descriptive sketch of IMP2 regulation network.  Figure was adapted from Cao et al. (2018). 
Several IMP2/p62 mRNA targets have been revealed associated with cancer initiation 
and progression, as IGF2, UCP1, C-Myc, and Let-7 miRNA (Figure 7 Cao et al., 2018). 
High expression levels of IMP2 activates IGF2/PI3K/Akt/mTOR pathway, and stimulate 
cancer cells proliferation, migration, and invasion (Dai et al., 2017; Mu et al., 2015; 
Waly et al., 2019). Furthermore, it has been reported that mRNAs of LIMS2, TRIM54, 
and LAMB2 are targeted by IMP2, increasing the migration ability of cancerous cells, 
cytoskeleton, and stimulating their metastatic behavior (Boudoukha et al., 2010; 
Manieri et al., 2012; Schaeffer et al., 2012). Also, wnt/β-catenin pathway is targeted by 
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 Reported RNA target sequences of IMP 
The clear identification and characterization of IMP targets are still not completely clear 
and needs more investigations (Biswas et al., 2019). The development in RNA-protein 
interaction detection methods revealed many target nucleotide sequences of RBPs 
(see Table 1; Biswas et al., 2019; Jia et al., 2018; Popova et al., 2015).   
Table 1: Reported RNA target sequences of IMP. 
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(Jia et al., 
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  IMPsb repetition  
 
a: tested on either IMP1 or IMP3, and due to the high structure similarity might bind to both; b: the 
repetition number of each nucleotide sequence differ based on IMP target. Abbreviations: 
electrophoretic mobility shift assay (EMSA), photoactivatable ribonucleotide - enhanced crosslinking 
and immunoprecipitation (PAR-CLIP), enhanced-CLIP (eCLIP), heteronuclear single quantum 
correlation (HSQC), and systematic evolution of ligands by exponential enrichment (SELEX). 
 
1.3 Biophysical methods used in drug discovery 
Several biophysical and structural techniques are commonly used for small-molecule 
ligand detection and screening for binders / inhibitors (Renaud et al., 2016). These 
methods detect minimal changes in fluorescence, temperature, electrophoresis and 
refractive index, etc (Ciulli, 2013). 
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1.3.1 Fluorescence polarization assay 
Fluorescence polarization (FP) assay is widely used to investigate molecular 
interactions, and enzymatic activity through direct and competitive binding assays 
(Burke et al., 2003). FP assay have been used widely in direct screening for enormous 
range of targets, and they are adopted for high-throughput screening (HTS) (Hall et al., 
2016). Furthermore, FP assay are valuable, reliable, and low-cost screening approach 
for inhibitors for protein‐nucleic acid and protein‐protein interactions (Hall et al., 2016). 
 
Figure 8 : Concept of fluorescence polarization assay in detection of protein interactions. Figure was 
adapted from Cheow et al. (2014). 
When a fluorescently labeled molecule is exposed to a polarized light at certain 
wavelength, it is excited and then emits light with a certain degree of polarization which 
is inversely correlated with the molecular rotation rate (Moerke, 2009). Small 
fluorescently labeled molecules rotate fast, and the received light by perpendicular or 
/ and parallel filters disappears rapidly and then the polarization value becomes low 
(Cheow et al., 2014). After binding to a macromolecule, the rotation becomes slower 
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1.3.2 Differential screening fluorometry / thermal shift assay  
The concept of the thermal shift assay (TSA) based on the observation that when the 
protein is gradually heated, it denatures and loose the 3-dimensional structure. The 
temperature at which the denatured protein fraction is equals to the renatured fraction 
is called melting temperature (Tm) (Huynh and Partch, 2015). The denaturation is no 
longer reversible at temperature higher than Tm (Huynh and Partch, 2015). Addition of 
a fluorescent dye as Sypro Orange incorporated to the protein, as the denaturation is 
increased, the dye-protein fraction increases, and the measured fluorescence signal is 
increased (Figure 9 Bruce et al., 2019). At higher temperatures, the denatured protein 
is aggregated together, and Sypro Orange dye is liberated (Bruce et al., 2019). Several 
factors may interfere with protein melting point as pH, salts, drugs, and mutations 
(Crowther et al., 2009). The binding of low molecular weight molecules may stabilize 
the protein complex and increase the melting temperature or may destabilize the 
protein complex and decrease the melting temperature (Senisterra et al., 2012). 
 
Figure 9 : Principle of thermal shift assay in detection of protein interaction. Figure was adapted from 
Bruce et al. (2019). 
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1.3.3 Microscale thermophoresis  
The concept of microscale thermophoresis (MST) is based on detection of minimal 
changes in thermophoresis (Figure 10 Liu et al., 2015). The movement of molecules 
inside the solution under a temperature gradient, relies  on a diversity of molecular 
properties as charge, size, polarity and hydration shell size (Jerabek-Willemsen et al., 
2011). The binding of a small molecule to protein change its molecular properties and 
decrease the velocity of movement under the thermophoresis gradient (Jerabek-
Willemsen et al., 2011). MST technique is extremely sensitive and detect any alteration 
in the molecular properties, permitting for an accurate quantification of molecular 
measures (Rainard et al., 2018). MST quantify high-affinity interactions with 
dissociation constants in picomolar range (Rainard et al., 2018). Furthermore, MST 
assay detect protein–protein interactions in pure mammalian cell lysates under semi 




Figure 10: Principle of microscale thermophoresis technique in detection of protein interaction. Figure 
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1.3.4 Saturation transfer difference - nuclear magnetic resonance 
Saturation transfer difference (STD) nuclear magnetic resonance (NMR) spectroscopy 
is a robust and reliable fluorescence free orthogonal method (Figure 11 Viegas et al., 
2011). STD-NMR used not only for investigating the protein–ligand interactions, but 
also predict the mode of binding pose (Haselhorst et al., 2009; Streiff et al., 2004). 
STD-NMR method identify the binding epitopes of a bound ligand to its target protein. 
The close protons of the ligand into the protein surface receive a higher degree of 
resonance saturation, and this strengthen STD spectrum signal (Haselhorst et al., 
2009). Protons with less interaction or even protons that far from the protein surface 
and not involved in the ligand protein interactions, have low or no STD-NMR spectrum 
signal (Barile and Pellecchia, 2014). Therefore, the STD-NMR method gives an 
expectation about the ligand pharmacophore and it’s an excellent tool for further 
optimization of the ligand structure (Barile and Pellecchia, 2014). 
 
Figure 11 : Principle of STD-NMR in characterization of binding mode. Figure was adapted from Viegas 
et al. (2011). 
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1.4 Aim of the present study  
We hypothesized that inhibition of the activity of IMP2 might be a novel and 
promising therapeutic approach for cancer therapy (Figure 12). 
Therefore, we established in vitro studies for target validation, set up a screening assay 
for small molecule inhibitors of IMP2, and test the biological activity of the obtained hits 
in vitro and in vivo. 
   
 
 
Figure 12: Hypothesis to be tested. Inhibition of IMP2 with small molecules might be a promising 
therapeutic approach in cancer therapy. Homologous IMP2 model was generated by Phyr 2 Protein 
Homology Recognition Engine (Kelley et al., 2015); graphical processing was done by PyMOL software 
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2.1.1 In vitro validation of IMP2 as a promising target in cancer therapy 
2.1.2 Effect of IMP2 knockdown/knockout on cell viability and proliferation 
 IMP2 knockdown impact on cell proliferation  
siRNA knockdown approach was used to reduce IMP2 expression in SW480, and 
Hep3B cells. IMP2/p62 expression were knocked down with mixture of siRNAs in both 
SW480 and Hep3B cells, results were confirmed by Western blot (Figure 13A, B).  
 
IMP2 knockdown cells were seeded in equal densities to their respective control cells 
(random siRNA treated cells) and treated under the same conditions. Cell viability was 
measured 72 h after siRNAs treatment and normalized to their respective controls. 
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Figure 13 : Impact of IMP2 knockdown on cell viability. The siRNA knockdown approach was 
used to reduce IMP2 in SW480, Hep3B cells. Mixture of siRNAs were used to knockdown 
IMP2 expression, and control cells (Co) were transfected cells with random siRNA. (A), (B) 
Representative Western blots show reduction of IMP2/p62 expression after knockdown of 
IMP2. IMP2 signal intensities were normalized to the tubulin signal. Data represent mean ± 
SEM; n = 3 (4,2,2 replicates). (C) Cell viability was measured with MTT 72 h after incubation 
with siRNA. Data were normalized to their respective controls. Data represent mean ± SEM; n 
= 5 (9,9,3,3,3, replicates). P value was calculated either with ANOVA or Mann-Whitney test.  
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 IMP2 knockout impact on cell proliferation via MTT 
CRISPR/Cas9 approach was established in our lab to knockout IMP2. Multiple cycles 
of CRISPR/cas9 trials by Tarek Kröhler led to biallelic knockout of IMP2 in HCT116, 
and monoallelic knockout in SW480, and Huh7 cells. Western blot (WB) was done to 
confirm the complete knockout in HCT116, and partial knockout in SW480, and Huh7 
cells (Figure 14A, B). The difficulty of growing cells from single cell colony in SW480, 
and Huh7, supports that IMP2 is essential for cell proliferation.  
 
IMP2 knockout cells were seeded in equal densities to their respective parental control 
cells and treated under the same conditions. Cell viability was measured with MTT 96 
h after seeding and normalized to their respective controls. Cellular proliferation was 
reduced significantly after IMP2 knockout in the tested cells (Figure 14C). 
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Figure 14 : Impact of IMP2 knockout on cell viability. IMP2/p62 expression was reduced in HCT116, 
SW480, and Huh7 cells by Tarek Kröhler using CRISPR/Cas9 approach. Control cells were the 
respective parental cells (Co). (A), (B) WB results show reduction of IMP2 expression after knockout of 
IMP2. IMP2 signal intensities were normalized to tubulin signal. Data represent mean ± SD; n = 2 (one 
replicate), except in HCT116 n = 3 (1,1,3 replicates). (C) Cell viability was measured with MTT 96 h after 
cell seeding. Data were normalized to their respective controls. Data represent mean ± SEM. For 
HCT116 n = 5 (30,6,6,9,9 replicates); SW480 n = 4 (30,3,3,6 replicates); Huh7 n = 2 (30,3 replicates). 
P value was calculated either with ANOVA or Mann-Whitney test.   
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 IMP2 knockout impact on proliferation via ECIS 
The MTT assay is able to predict cell proliferation based on the metabolic activity of 
cell mitochondria. The alteration in cell metabolism and mitochondrial content might 
affect cell viability (Rai et al., 2018). 
Electric Cell-Substrate Impedance Sensor (ECIS) provides a real-time estimation of 
cell proliferation (Szulcek et al., 2014; Zudaire et al., 2008) by measuring the 
impedance of adherent cell layers to the well surface. In addition, altered impedance 
also allows assessment of changes in cellular behavior, such as, adhesion, which has 
been shown to be affected by IMP2 (Szulcek et al., 2014; Xing et al., 2019).  HCT116 
cells after plate coating with rat tail collagen were suitable to be used in ECIS method 
to evaluate the role of IMP2 knockout on proliferation rate.  
Our findings showed IMP2 knockout cells have lower proliferation rate compared to 
the control cells (Figure 15). ECIS results further supported the role of IMP2 in cell 
proliferation.  
 
Figure 15 : Effect of IMP2 knockout on cell proliferation. Cell impedance was measured in real-time 
using ECIS method. HCT116 parental cells and IMP2 CRISPR/cas9 knockout cells were seeded in 
equal numbers and conditions. Cell impedance was normalized to the starting impedance point (0-4 h). 
Results 
ــ ــــــــــــــــــــ ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــ ـــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 21  
 
Data represent mean ± SEM; n = 2 (triplicates). IMP2 knockout HCT116 cells were received from Tarek 
Kröhler. 
2.1.3 Influence of IMP2 reduction on IMP1 and IMP3 expression 
The mRNA of IMP1 and IMP3 may serves as potential targets for IMP2 regulation. For 
this purpose, the expression of IMP1 and IMP3 after IMP2 knockdown/knockout was 
investigated by WB and RT-qPCR. Duplicate samples of confirmed IMP2 
knockout/knockdown were used to investigate IMP1 and IMP3 expression.  
 
 Potential inter IMP interactions in colon cancer cells 
We observed that IMP1 expression was upregulated and IMP3 expression was down 
regulated in HCT116 cells (RNA and protein levels). In SW480 cells, the expression of 
IMP1 and IMP3 was down regulated (RNA and protein levels) (Figure 16A-C).  
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Figure 16 :Impact of IMP2 knockout on IMP1 and IMP3 expression in colon cancer cells. Western blot 
and RT-qPCR data show the expression of IMPs after IMP2 knockout. (A), (B) WB shows IMP2 biallelic 
(bKO) knockout in HCT116 cells, and monoallelic (mKO) knockout in SW480. WBs from duplicated 
samples show IMP1 and IMP3 expression after IMP2 knockout. Parental cells were used as controls 
(Co). IMPs signal quantification was normalized to tubulin control signal. Data represent mean ± SD; n 
= 2 (one replicate). (C) represent IMPs mRNA expression measured with RT-qPCR. IMPs expression 
was normalized to the expression of β-actin housekeeping gene. Data represent mean ± SEM; n = 2 
(6,3 replicates). P value was calculated either with one-way ANOVA or Mann-Whitney test.    
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 Potential inter IMP interactions in liver cancer cells after IMP2 knockout 
In the protein levels, we observed that IMP1 was upregulated and IMP3 was down 
regulated in Huh7 cells (Figure 17A, B). Furthermore, the IMPs expression was 
unchanged in Huh7 cells (Figure 17C).  
 
Figure 17: Impact of IMP2 knockout on IMP1 and IMP3 expression in liver cancer cells. Western blot 
and RT-qPCR data show the expression of IMPs after IMP2 knockout. (A), (B) WB shows IMP2 partial 
monoallelic (mKO) knockout in Huh7. WBs from duplicated samples show the expression of IMP1 and 
IMP3 after IMP2 knockout. Parental cells were used as controls (Co). IMPs signal quantification was 
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normalized to tubulin control signal. Data represent mean ± SD; n = 2 (one replicate). (C) represents 
IMPs mRNA expression measured with RT-qPCR. IMPs expression was normalized to the expression 
of β-actin housekeeping gene. Data represent mean ± SEM; n = 2 (6,3 replicates). P value was 
calculated either with one-way ANOVA or Mann-Whitney test.   
 
 Potential inter IMP interactions in liver cancer cells after IMP2 knockdown 
We observed that IMP1 and IMP3 expression were downregulated. The mRNA of IMP1 
in Hep3B cells was unchanged, and IMP3 expression was upregulated. In Plc/Prf/5 
cells, IMP1 expression was upregulated, and IMP3 was unchanged (Figure 18A-C).  
 
Our results might predict the potential inter IMP regulations and these findings need 
more experiments to draw a reliable conclusion. 
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Figure 18 : Impact of IMP2 knockdown on IMP1 and IMP3 expression in liver cancer cells. Western blot 
and RT-qPCR data show IMPs expression after IMP2 knockdown. (A) WB shows IMP2/p62 expression 
after IMP2 siRNA knockdown in Hep3B and Plc/Prf/5 cells. IMP2 knockout affect the expression of IMP1 
and IMP3. Cells treated with random siRNA were used as controls (Co). (B) IMPs signal quantification 
was normalized to tubulin control signal. Data represent mean ± SD; n = 2 (1 replicate). (C) represent 
IMPs mRNA expression measured with RT-qPCR. IMPs expression was normalized to the expression 
of β-actin housekeeping gene. Data represent mean ± SEM; n = 2 (6,3 replicates). P value was 
calculated either with one-way ANOVA or Mann-Whitney test.  
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2.2 IMP2 isolation, characterization, and primary screening for inhibitors 
2.2.1 Recombinant IMP2 isolation and characterization  
For the purpose of detection of inhibitors for IMP2 RNA interaction, production of large 
quantities of human IMP2 was required. Recombinant protein technology is an 
essential approach in the molecular biology that aimed to produce large quantities of 
proteins (Rosano and Ceccarelli, 2014). Recombinant IMP2 was isolated using 
immobilized-metal affinity chromatography (IMAC). Before starting the FP assay, the 
purity and integrity of IMP2 protein was confirmed by SDS-PAGE. Furthermore, 
Western blot confirmed the mass and identity of eluted IMP2 (Figure 19A, B). Since 
FP assays are based on the use of small labeled RNA sequences, we confirmed the 
absence of any RNase activity in the protein preparation under assay conditions 
(Figure 19C). Circular dichroism (CD) spectrometry confirmed the presence of α-helical 
and β-sheet secondary structure elements indicating correct folding of IMP2 (Figure 
19D). 
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 Figure 19 : Isolation and characterization of recombinant IMP2 protein. Histidine-tagged IMP2 was 
overexpressed in E. coli and isolated via affinity chromatography using a HisTrap HP Nickel–Sepharose 
column. Protein was eluted in an imidazole buffer with increasing imidazole concentrations. (A) Fractions 
were collected and run on an SDS-PAGE (lanes 5 – 7). A 10-180 kD protein ladder marker (M), the 
unpurified cell lysate (1), the column flow-through (2), and washing buffers (3 – 4) were also run on the 
gel. The gel was stained with Coomassie blue and revealed the pure IMP2 protein in the 300 mM and 
700 mM imidazole fractions (lanes 6 and 7). IMP2 containing fractions were combined and concentrated. 
(B) The identity of the 67 kDa protein IMP2 was confirmed by Western blot analysis. (C) The absence 
of RNase activity was confirmed via RNA integrity measurement of MCF7 RNA in the presence of eluted 
protein, as visualized on an agarose gel. M: 1 kb marker, 1: RNA incubated with storage buffer for 1.5 
h as a control, 2: RNA incubated with IMP2 for 1.5 h on ice, 3: RNA incubated with IMP2 for 1.5 h at 
room temperature (RT). (D) Circular dichroism (CD) spectroscopy was used to verify the correct protein 
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2.2.2 IMP2 amino acid sequence confirmation 
Liquid Chromatography with Tandem mass spectrometry (LC-MS/MS) showed 
digested fragments with trypsin cover more than 60% of IMP2 amino acids identity 
(Figure 20). 
 
Figure 20 : IMP2 amino acid sequence confirmation. Mass spectrometric analysis of IMP2 after digestion 
with trypsin protease and analyzed using high resolution LC-MS/MS. Sequences shown in red were 
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2.2.3 FP primary screening 
 Establishment of FP assay  
For the purpose of functional inhibition of IMP2 RNA interaction, known IMP2 RNA 
binding sequences were involved in different RNA probes. Two RNA oligonucleotides 
were designed as IMP2 binding partners (RNA_A/B). A control RNA oligonucleotide 
was used as a control sequence (RNA_C). The sequences of RNA probe used in FP 
assay are summarized in Table 2. 
Table 2 : Summary of probe sequences used in FP assay validation. 
 
 
The FP signal was tested at different DMSO concentrations between 0 and 10% (v/v), 
FP signal was stable up to 10% DMSO. A final concentration of 5% DMSO was 
selected for later screening experiments (Figure 21A, B). FP signals were measured 
at different time points, the FP signal was clearly stable after 1 h of incubation at room 
temperature until at least for 3 h, a 1.5 h of incubation was considered appropriate for 
the further screening experiments (Figure 21C, D).  
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Figure 21 : Fluorescence polarization assay development and optimization. (A, B) The DMSO tolerance 
of the FP assay was determined by using 1 nM of either the (A) RNA_A or the (B) RNA_B probe, IMP2 
(120 nM for RNA_A and 160 nM for RNA_B), and varying concentrations of DMSO (v/v). Unlabeled 
RNA was used as a control. (C, D) The stability of the protein-RNA complex was assessed for 5% DMSO 




The robustness of  FP assay was investigated using low controls (flurophore alone) 
and high controls (IMP2 and flurophore). The Z’ value was 0.9 for both RNAs and 
confirmed that the FP assay was robust and appropriate for further competitive 
screening (Figure 22A-C).  
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Figure 22 : The robustness of FP assay. (A, B) To determine the robustness of the FP assay, 192 
samples of low controls (LC), containing 1 nM (A) RNA_A or (B) RNA_B without IMP2, and 192 samples 
of high controls (HC) containing additionally 120 nM and 160 nM IMP2 for RNA_A and RNA_B, 
respectively, were assessed at 5% DMSO in the FP assay after 1.5 h incubation. (C) Z′-factors were 
calculated based on the obtained data.  
 
 
A lead inhibitor (2-((8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(1-
phenylethyl)acetamide) was published by Mahapatra et al. (2014) for IMP1 RNA 
interaction. The used RNA probe (ACAGAACAA) in the FP screening assays share 
structure similarity with RNA_A (ACACAACA). A competitional FP assay was done for 
IMP1 lead compound for its potential off target inhibition of IMP2 RNA_A / B interaction. 
The solubility limit of IMP1 lead compound was 62.5 µM determined by measuring the 
change in absorbance at 620 nm. Different concentrations from IMP1 lead compound 
were tested against RNA_A and RNA_B. IMP1 lead compound did not inhibit IMP2 
interaction either with RNA_A or RNA_B (Figure 23). 
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Figure 23 : Characterization of IMP1 lead compound interaction with IMP2 RNAs. Competition 
experiments were conducted using fixed concentrations of labeled RNA_A/B (1 nM), and IMP2 200 nM, 
and varying concentrations of IMP1 lead compound. Mixture of labeled RNA_A/B (1 nM), and IMP2 200 
nM was used as a negative control, Co(-), and labeled RNA_A/B (1 nM) were used as a positive control, 
Co(+). Data represent means of FP values of duplicates ± SD; n = 2.   
 
 
We developed the fluorescence polarization assay for detecting potential hits capable 
to inhibit IMP2 RNA interactions. Serial dilutions of IMP2 were titrated against 1 nM of 
three different RNA sequences; IMP2 showed high affinity to RNA_A-B with EC50 
values of 60.7 nM and 80.5 nM, respectively. No binding occurred with control RNA_C. 
BSA was used as a control protein and titrated against RNA_A/B, where no binding 
was detected (Figure 24A).  
RNA_A and RNA_B are target RNAs and RNA_C serves as a control sequence. 
Saturation experiments were performed by titrating 1 nM of fluorescein labeled RNAs 
with a serial dilution of IMP2 protein or unrelated protein BSA.  
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None labeled RNA_A and RNA_B used to test displacement of labeled RNAs in 
competitive FP assay, serial dilutions of their different RNA sequences titrated against 
200 nM and 1 nM labeled RNAs. The IC50 values for RNA_A and RNA_B were 5.3 and 




Figure 24 : Characterization of IMP2 functional binding to different RNA targets by FP assay. Direct and 
competition binding assays were performed by FP assay using full-length IMP2. Different RNAs and 
substrates were used to test the specificity of IMP2: RNA interactions. (A) Fluorescein-labeled target 
RNA sequences (RNA_A/B) and control sequence (RNA_C) were used in saturation experiments by 
titrating 1 nM RNA with a serial dilution of IMP2 protein or unrelated protein BSA. (B) Competition 
experiments were conducted using fixed concentrations of 1 nM RNA_A/B, 200 nM IMP2, and varying 
concentrations of the respective non-labeled RNA as a competitor. (C) Half maximal effective 
concentrations in saturation assay (EC50 FPsat) and half-maximal inhibitory concentrations in competition 
assay (IC50 FPcomp) were calculated using non-linear regression analysis. Data are represented as 





ــ ــــــــــــــــــــ ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــ ـــــــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 34  
 
 FP-based primary screening  
A total number of 46 and 38 compounds achieved more than 50% inhibition with IMP2 
for RNA_A and RNA_B, respectively. Twenty-five and sixteen active compounds were 
excluded as a result of quenching the fluorescence intensity or the auto-fluorescent 
nature for RNA_A and RNA_B, respectively (Figure 25A, B).  
 
 
Figure 25 : FP primary screening and characterization of hit compounds. In a primary screening, 1,428 
compounds were screened for RNA_A and 1,175 compounds for RNA_B in an FP assay at a final 
compound concentration of 150 µM. (A) The scatter plot represents FP mean values of responses 
normalized to the response of non-labeled RNAs, used as a positive control. (B) Mean fluorescence 
intensities of screened compounds were plotted against % inhibition. Compounds achieving more than 
50% inhibition without interfering with the fluorescence intensity were considered as a hit. The dashed 
lines indicate the hits threshold. 
 
 Pluronic® F-127 effect on FP assay findings 
Pluronic® F-127 is a non-ionic polymer surfactant that have been used to facilitate 
solubilization of lipophilic probes. Pluronic® F127 has been used in broad range of 
therodiagnostic applications in biomedical and pharmaceutical sciences (Akash and 
Rehman, 2015; Maruyama et al., 1989). Pluronic® F-127 has been utilized to ease the 
dispersion of acetoxymethyl esters of fluorescent ion indicators such as indo-1, fura-2, 
fluo-3, fluo-4 and SBFI (Fan et al., 2011; Maruyama et al., 1989; Qu et al., 2016). The 
use of Pluronic® F-127 in our study revealed some false positive hits that were 
excluded from further examinations. A total of 13 active compounds were excluded 
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after addition of Pluronic® F-127 (Figure 26A). Only 16 and 12 compounds were 
considered as true hits for RNA_A and RNA_B, respectively. Ten compounds were 
common and able to inhibit IMP2 binding to both RNAs. Furthermore, the aggregated 




Figure 26 : Effect of Pluronic® F-127 on FP assay findings. The role of Pluronic® on FP assay was to 
rule out potential false positive results. (A) To minimize unspecific aggregation and, therefore, false-
positive results, 0.013% Pluronic® F-127 were added to FP buffer. The inhibitory effect of compounds 
31 – 33 was lost after addition of Pluronic® F-127, but not for compound 1. Data are represented as 
means ± SD, n = 1 (duplicates). (B) The IC50 value of compound 3 was increased from 26.7 to 123.2 
µM. Data represent mean ± SD, n = 2 (duplicates). 
 
 
 Dose response studies of hit compounds 
Hit compounds belong into either benzamidobenzoic acid compounds group (class A), 
and urea compounds group (class B). The IC50s were measured by FP assay, results 
revealed IC50 values in range of 65.3 to 120.9 µM for RNA_A and 72.3 to 333.3 µM for 
RNA_B (Figure 27A, B). 
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Figure 27 : FP primary screening and characterization of hit compounds.  (A) and (B) Dose-response 
studies were performed with three representative hit compounds (compounds 4, 7, 8) against (C) 
RNA_A and (D) RNA_B in the FP-based competition assay. Competition assays were conducted using 
fixed concentrations of RNA_A/B (1 nM), and IMP2 (200 nM), and varying concentrations of hit 
compounds. Data are represented as means of FP values ± SD, n = 2 (duplicates). 
 
The 10 most promising hits belonged either to the benzamidobenzoic acid class (A) or 
the ureidothiophene class (B) (Figure 28A, B; Supplementary data: Table 1, 2).  
 
Figure 28 : Chemical classification and IC50s of hit compounds. (A) and (B) The chemical structures and 
IC50 values of hit compounds (cmpd) from class A (benzamidobenzoic acid group, A) and class B 
(ureidothiophene group, B) compounds. IC50 values were calculated based on competition experiments, 
using the established FP assay (1 nM RNA_A/B, 200 nM IMP2, and varying concentrations of hit 
compounds). N = 2 (duplicates). 
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 Correlation of the half inhibitory concentration with competitive inhibitory 
constant 
The inhibition constant (Ki) is kinetically defined as the ratio of association rate constant 
over dissociation rate constant (koff/kon). The Ki value is an intrinsic indicator of the 
binding affinity, even though it may depend on the substrate concentration and affinity. 
The IC50 value additionally depends on the enzyme concentration. 
The well-known Cheng-Prusoff equation is commonly used for the calculation of the 
competitive binding inhibitions (Cheng and Prusoff, 1973). The Cheng-Prusoff 
equation is not valid in FP competitive binding assays. For this purpose, a newly 
developed and validated mathematical equation that was generated by Nikolovska-
Coleska et al. (2004). Accordingly, this equation is Ki = [I]50 / ([L]50 / EC50 + [P]0 / EC50+ 
1).  where  [I]50 represents the concentration of the free inhibitor at 50% inhibition (FP 
IC50 value), [L]50 represents the concentration of the free labeled RNA probes (1 nM) 
at 50% inhibition, EC50 is half maximal effective concentrations (60.7 nM for RNA_A 
and 80.5 nM for RNA_B), and F[P]0 is the free IMP2 concentration at 0% inhibition (200 
nM). The Ki values of final hit compounds were summarized in Table 3. 
     Table 3: Summary of Ki values of hit compounds. 
Class A Class B 
 Ki (µM)  Ki (µM) 
cmpd # RNA_A RNA_B cmpd # RNA_A RNA_B 
1 25.9 47.5 5 27.0 43.0 
2 25.3 43.0 6 28.1 67.9 
3 28.7 39.5 7 23.0 21.0 
4 18.9 36.6 8 16.9 20.7 
   9 15.2 32.2 
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2.3 Secondary confirmation of IMP2-hit compound interactions  
2.3.1 Confirmation of IMP2-hit compound interaction with thermal shift assay 
TSA was used to further confirm hit compounds IMP2 interaction. The Tm of IMP2 was 
43ºC and change in melting temperature after addition of hit compounds were 




Figure 29 : Thermal shift assay confirmation of hit compounds. Thermal shift assays were performed to 
confirm IMP2-hit compound interaction at fixed concentrations of IMP2 (4.5 µM) and non-labeled RNA 
(100 µM) or hit compound (100 µM), respectively, measuring the fluorescence of Sypro Orange. (A) 
Representative melting curves demonstrate a shift in the IMP2 melting temperature (Tm) resulting from 
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the binding to either RNA (blue) or hit compound 8 (red) compared to the control (gray). (B) Melting 
temperature shifts (∆Tm) resulting from compound interactions were quantified and compared to the 
non-labeled RNA control. Date are presented as means ± SD, n = 2 (one replicate). 
 
2.3.2 Confirmation of IMP2-hit compound interaction with microscale 
thermophoresis 
The thermophoresis movement of a fluorescent NTA His tagged IMP2 was changed 
dependently to the increase of IMP2 bound fraction with compound # 9.  IMP2 showed 
a stronger reduction in fluorescence in the bound state compared to the unbound state. 
The dissociation constant (Kd) is fitted to 43.2 ± 6.9. The dose response titration of 
compound # 9 that was measured by FP and MST assays, showed similar range of 
IC50 values (Figure 30A-D). 
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Figure 30: Comparison of IC50 values for compound # 9 with MST and FP assays. A ligand titration 
experiment was done with MST technique to confirm the measured IC50 results with FP assay (A) The 
thermophoresis movement of a fluorescent NTA His tagged IMP2 was changed dependently to the 
increase of IMP2 bound fraction with the compound # 9. (B) The normalized fluorescence difference [%] 
reflects the thermophoresis movement. A final concentration of 300 nM of IMP2 was titrated against 
different concentration of compound # 9. (C) FP-based competition experiments were conducted using 
1 nM of RNA_A/B as probe, 200 nM of IMP2, and different concentrations of compound # 9. Data are 
represented as mean FP values of each duplicate ± SD. IC50 values were determined using non-linear 
regression analysis (D) The IC50 values for MST and FP (RNA_A, and RNA_B) are represented in µM.   
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2.3.3 Confirmation and characterization of IMP2-hit compound interaction with 
STD – NMR 
IMP2 has many flexible loops making the crystallization of full length IMP2 a huge 
burden. STD-NMR (orthogonal) method was applied as an alternative to have a closer 
look into the binding pose. Furthermore, STD-NMR was utilized to further confirm 
ligand-protein interaction by a fluorescence free method (Becker et al., 2018; Viegas 
et al., 2011). Typically, the proton with the strongest STD effect is used to normalize 
the signals of the other protons resulting in values between 0 - 100%.  
 Establishment and optimization of STD-NMR experiment 
The STD-NMR buffer was optimized for protein stability and generation of clear 
spectra. STD-NMR experiments were performed at fixed concentrations of 2.5 or 5 µM 
IMP2. Hit compounds were used either in concentrations of 250 µM for compound 2 
and 3 or 500 µM for compounds 4 - 6 and 13 - 14. Concentrations were selected based 
on the solubility limit in 10% DMSO D6. A control spectrum was performed under the 
same conditions without a protein to test for artifacts. The theoretical chemical shifts 
range was predicted by Chemical Communications (ChemDraw) software and the area 
of each peak was calculated by integration. 
 Mode of interaction of compound # 4 with IMP2 
The overlay of the off-resonance and STD spectra of compound # 4 in presence of 
IMP2 predicts the mode of interaction of IMP2 compound # 4 complex. A first 
observation was that protons H-1, H-2, and H-3 of the benzoic acid ring are interacting 
strongly with the protein (H-1 73.7%, H-2 100% observed together with H-11, H-3 75.7 
% observed together with H-6/7; Figure 31).  
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Figure 31 : Interaction mode of compound # 4 predicted by STD-NMR. STD-NMR experiment results of 
compound # 4 in complex with IMP2.The reference spectrum is shown in red, and the STD difference 
spectrum is shown in green. Overlaid STD off-resonance and STD effect spectra were normalized to 
the signal of H2, and 11. 
Secondly, within the middle ring, chemically equivalent protons H-6 and H-7 (75.7%; 
observed together with proton H-3) presumably are in closer proximity to IMP2 than H-
4 and H-5 (61.4%). Finally, the terminal phenyl moiety seems to interact less strongly 
overall (H-8/9 50.6%, H-10/12 52.7 %, H-11 100% observed together with proton H-2). 
Dr. Martin Empting participated in writing this result part. 
 Overall summary of IMP2-hit compound mode-of-interaction 
STD-NMR was successfully performed with compounds 2-6 as well as 13 and 14. 
Among this set of STD-NMR-investigated compounds were three compounds 
belonging to class A (2-4) and four compounds belonging to class B (5, 6 and 13, 14). 
For the latter two compounds (13, 14), which inhibit only RNA_A. The overall STD 
effect was not very prominent and did not allow for a conclusive result. This might 
explain different affinities of hit compounds for multiple RNA binding domains. The 
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overall STD-NMR results of all tested compounds were summarized in Figure 32  
(STD-NMR data are shown in Supplementary data: Figure 1). 
 
 
Figure 32 : Colored epitopes of hit compounds based on STD-NMR data. Colored epitopes of hit 
compounds display the interaction mode of IMP2 legend complex. Colored dots represent the 
percentage of relative STD effect and shown as: red dots represent of 100% relative STD; purple dots 
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2.3.4 In silico confirmation and characterization of IMP2-hit compound 
interaction 
molecular docking is commonly used in drug optimization and validation such as 
pharmacophore modeling and quantitative SAR studies (Meng et al., 2011). We 
generated docking models for IMP2 that might be used later for structure optimization 
or virtual screening. The first generated model was a homology model of IMP2 RRM1 
domain in complex with ACAC and CCCC RNA binding motifs using the homologous 
IMP3 RRM12 structure. A second model was a homology model of IMP2 KH34 
domains in complex with CAC/CCC and CGGA RNA binding motifs using the 
homologous IMP3 KH34 structures (Figure 33). 
 
Figure 33 : Homology models for the molecular docking studies. A homology model for IMP2 RRM1 was 
generated using a reported NMR structure of IMP2 an X-ray structure of IMP3 in complex with RNAs 
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(ACAC and CCCC). Another homology model for IMP2 KH34 was generated using a reported X-ray 
structure for IMP2 and an X-ray structure for IMP1 in complex with RNAs (CAC/CCC, and CGGA). 
 
 Molecular docking of compound # 4 in the RRM1 binding domains 
With the aim to derive a plausible binding pose for hit compounds and based on the 
assumption that our IMP2-RNA-interaction inhibitors act in an RNA-competitive 
manner, we docked compound 4 (representative for class A) to the RRM1 and KH34 
RNA binding sites. The highest ranked docking pose reflected some key observations 
from the STD-NMR experiment. 
 
2.3.4.1.1 Compound # 4 and inhibition of IMP2-RNA (ACAC) complex 
In this hypothetical IMP2 RRM1 ACAC interaction complex, the benzoic acid head 
group interacts strongly with the protein, the carbonyl function being involved in a salt 
bridge with nearby Arg90 sidechain and H-3 being the most solvent exposed (less 
interacting) proton in this ring. Protons H-4 to H-7 showed a mixed solvent exposure 
profile, which is in agreement with the observed STD effect. Finally, in this docking 
pose the terminal phenyl ring is the part of the molecule, which is mostly exposed to 
the solvent although it is predicted to interact with Ser76 via a hydrophobic arene-H 
interaction with the proton at the α-carbon of the residue (Figure 34A, B). Dr. Martin 
Empting participated in writing this result part. 
  
2.3.4.1.2 Compound # 4 and inhibition of IMP2-RNA (CGGA) complex  
The RNA (CGGA) sequence was not involved either in RNA_A or RNA_B probes used 
in the competitive FP assays. In order to predict whether compound # 4 interact with 
RNA (CGGA) in IMP2 KH 4 domain, docking studies were performed. In the 
hypothetical IMP2 KH4 CGGA complex, the benzoic acid ring is predicted to interact 
with Gly529 via a hydrophobic arene-H interaction with the proton at the α-carbon of 
the residue. Protons H-4 to H-7 showed a mixed solvent exposure profile, which is in 
agreement with the observed STD effect. The proximal phenyl ring is predicted to 
interact with Arg547 via a hydrophobic arene-H interaction with the proton at the α-
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carbon of the residue. Finally, in this docking pose the terminal phenyl ring is the part 
of the molecule, which is mostly exposed to the solvent although it is predicted to 
interact with Arg547 and Asp548 via a hydrophobic arene-H interaction with the proton 
at the α-carbon of the residue (Figure 34C, D). 
 
 
Figure 34 : Molecular docking of compound # 4 in IMP2 binding domains. (A) and (B) show the 3D and 
2D interactions of compound 4 with RNA (ACAC) in IMP2 RRM1. (C) and (D) show the 3D and 2D 
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2.4 Biological activity assessment of final hit compounds (potency, 
specificity, and safety) 
2.4.1 Biological activity of final hit compounds 
 IMP2 expression in different cancer cell lines 
Different cell lines were used to estimate the biological activity of hit compounds. Colon 
cancer cells (HCT116, and SW480) and liver cancer cells (HepG2, Hep3B, and Huh7) 
expressing high IMP2 levels. MCF7 cells are not expressing IMP2 and were used as 
a control cell lines (see Figure 35 and Cancer Cell Encyclopedia (Ghandi et al., 2019)). 
Since hit compounds are dissolved in DMSO solvent, cell tolerance to different 
concentrations of DMSO was tested in different cell lines (Supplementary data: Figure 
2, 3).  
 
Figure 35 : IMP2/p62 expression in different cancer cell lines. IMP2/p62 expression were assessed 
before biological experiments in parental MCF7, SW480, HCT116, Huh7, HepG2, and Hep3B cells and 
compared to their respective IMP2 knockout/knockdown cells. MCF7 cells served as control cells in the 
biological assessment of hit compounds. IMP2 knockout was performed by CRISPR/Cas9 in HCT116, 
SW480, HepG2 and Huh7 cells. IMP2 knockdown was done with siRNA transfection in Hep3B cells. 
The immunodetection of tubulin served as a loading control. N = 3 (1-2 replicates). 
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 Effect of hit compounds on cancer cell viability 
Dose-response studies were performed for hit compounds. The cell viability was 
measured via MTT 96 h after treatment with hit compounds. The lowest biological 
activity was observed in MCF7 representing higher affinity of hit compounds on target. 
SW480 cells were the most sensitive among IMP2 expressing cells. Compound # 3 
from class A, and compound # 5 from class B have the weakest potency (Figure 36A, 
B). 
Figure 36 : Biological activity of final screening hits. The biological activity of hit compounds was 
assessed using MTT assay in cancer cell lines expressing high IMP2 levels (HCT116, SW480, HepG2, 
Huh7, Hep3B) or low IMP2 levels (MCF7). (A) represents a dose-response studies of a representative 
hit compound. Cell viability was measured 96 h after treatment with hit compounds (1-80 µM) or DMSO 
solvent control. (B) IC50 values were calculated using non-linear regression analysis. Dots represent 
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IC50 values of hit compounds (largest circle ≥ 80 µM, smallest circle 18.2 µM). The dot plot was 
generated with Python 3.8.1 software. n = 5 except in HCT116 and Hep3B; n = 2 (triplicates).  
 
 Assessment of hit compound on-target activity via MTT 
HCT116, and SW480 cells were selected based on target validation and IC50 values 
to test the potency of hit compounds on parental cells compared to IMP2 reduced cells. 
Cellular proliferation was measured with MTT 96 h after treatment of hit compounds at 
different concentrations. 
Hit compounds showed more potent effect on all cells expressing higher levels of IMP2 
confirming target specificity (Figure 37A-B).  
 
Figure 37 : Target specificity of hit compounds. The cell viability was measured with MTT in parental 
and IMP2 knockout cells to assess hit compounds affinity on target. IMP2 knockout cells were treated 
with either hit compounds or the respective DMSO solvent control (Co). (A) and (B) Hit compounds were 
employed at 80 µM for HCT116 and HepG2 cells, (C) Hit compounds were employed at 40 µM for 
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SW480 cells. Cell viability was normalized to the respective control cells. Data are represented as 
means ± SEM, n = 2 in HCT116 and HepG2 and n = 5 in SW480 (triplicates). 
 
 
Furthermore, the target specificity of hit compounds was assessed in dose dependent 
manner (5, 10, 20, 40, 80 µM) 96 h after treatment with hit compounds. Also, 72 h time 
point was investigated at concentrations of 40 µM and 20 µM (Data not shown). 
 
  Assessment of hit compound on-target activity via ECIS 
The measured viability via MTT after hit compounds treatment represents mixed 
cytotoxic and anti-proliferative effects. ECIS estimated the proliferation of HCT116 
cells after hit compounds treatment via readout parameter of cell spread and migration. 
Non-toxic concentrations (25 µM) were used to treat HCT116 parental and IMP2 
knockout cells. All hit compounds showed more potent inhibitory effect on parental 
cells compared to IMP2 knocked out cells (Figure 38A, B; Supplementary data: Figure 
4).  
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Figure 38 : Impact of hit compounds on cell proliferation in the absence of IMP2. Cell impedance of 
HCT116 was assessed by ECIS as a readout parameter for cell density and adhesion. (A) Both parental 
and IMP2 CRISPR/Cas9 knockout cells were seeded in equal numbers and treated with 25 µM 
compound 1 or DMSO solvent control (Co), respectively. (B) Bars indicate impedance differences 
between compound and control treatment for parental and IMP2 knockout cells, calculated for the 
timepoint 163-168 h. Data are represented as means ± SEM; n = 2 (triplicates). 
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2.4.2  Cytotoxicity of hit compounds on human cells 
 Effect of hit compounds on HUVEC cells 
HUVEC cells, a normal human cell line, are a commonly used cells to evaluate 
compounds safety profile. Since HUVEC cells are embryonic cells, they are expressing 
IMP2 (see The Human Protein Atlas). IMP2 is important for HUVEC cells proliferation, 
and growth and they might be targeted by hit compounds.  
Treatment of HUVEC cells with hit compounds after 72 h showed that class A hit 
compounds has above 50% viability even at 50 µM. Class B has more potent effect on 
HUVEC cells at 25 and 50 µM compared to class A (Figure 39). 
Our findings showed that the proliferation of HUVEC cells was reduced after treatment 
with hit compounds. The same findings were reported by Charlotte Dahlem after 
treatment HUVEC cells with compounds # 1 and # 9.  
 
 
Figure 39 : Effect of hit compounds on HUVEC cells. The cytotoxicity assessment of hit compounds was 
performed using normal human cells (HUVEC). Cell viability was measured with MTT 72 h treatment 
after hit compounds. Cell viability was normalized to their respective control. Data represent mean ± 
SEM; n = 1 (triplicates). 
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 Cytotoxicity of hit compounds on differentiated Huh7 cells 
Since HUVEC cells are expressing IMP2, it might not the best model for safety profile 
assessment. Another approach has adapted for cytotoxicity assessment of hit 
compounds using differentiated Huh7. The replacement of the fetal calf serum (FCS) 
in culture medium of Huh7/7.5 cells with their native adult human serum (HS), 
differentiate cells toward the normal behavior and alter several cancerous properties 
(Steenbergen et al., 2018). After differentiation of Huh7.5 cell, the growth is arrested, 
cells are polarized and have epithelial, cuboid morphology (Steenbergen et al., 2018). 
Cell viability was measured via MTT 96 h after treatment of differentiated and normal 
Huh7 with hit compounds. Compounds # 6, 7, 8, 9 and 10 affected the viability of 
normal Huh7, but not the differentiated cells. Compound # 4 significantly reduced the 
viability of both differentiated and non-differentiated Huh7 cells compared to the 
relative controls. Compound # 3 was highly toxic for differentiated Huh7 (Figure 40).  
 
Figure 40 : Effect of hit compounds on differentiated Huh7 cells. Huh7 cells were differentiated in human 
serum (HS) for 21 days. Huh7 and HS-differentiated Huh7 were treated either with 50 µM hit compounds 
or DMSO solvent control. Cell viability was determined by MTT 96 h after treatment with hit compounds. 
The cell viability was normalized to their respective control. Data are represented as means ± SEM; n = 
2 (triplicates). 
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 Influence of Huh7/7.5 cells differentiation on IMP expressions 
2.4.2.3.1 Impact of HS differentiation on IMP RNA levels 
 
To investigate whether the expression of IMPs was involved in Huh7 cells 
differentiation, IMPs expression was investigated on RNA and protein levels. Huh7.5 
cells were harvested at different time points (24h, W1, W2, W3) by Charlote Dahlem. 
Then, IMPs expression was investigated by RT-qPCR. A total of two housekeeping 
genes were used as control genes. The results of geNORM tool showed the expression 
of 18S is more stable compared to ß–actin housekeeping gene. The expression of 
IMPs was downregulated over the (21 day) incubation time (Figure 41A-C). However, 
the expression of both housekeeping genes was altered after huh7.5 differentiation. 
As a result, we cannot draw a conclusion based on qPCR data, since the cellular 
content of both cells are variable. This might indicate that the noticed down regulation 
in IMPs was caused by upregulation in the 18S housekeeping gene.  
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Figure 41: Influence of Huh7.5 differentiation on IMPs expression. The expression of IMPs was 
investigated over the period of HS treatment using RT-qPCR. IMPs expression in the differentiated 
Huh7.5 cells were normalized to 18S housekeeping gene. The expression of IMPs after HS treatment 
(24 h, W1, W2, W3) were normalized to the control FCS treated Huh7.5 cells. P value was calculated 
either with ANOVA or Mann-Whitney. Data represent mean ± SEM; n = 2 (triplicates). 
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2.4.2.3.2 Impact of HS differentiation on IMP protein levels 
Furthermore, the influence of HS differentiated Huh7 cells on IMPs expression was 
assessed on the protein levels. Samples were collected from Huh7 cells at different 
time points during HS treatment (W1, W2, W3), Huh7 cells treated with FCS for 24 h 
was used as a control cell. Western blot shows IMP1 expression was down regulated 
but neither IMP2 nor IMP3 were affected during Huh7 differentiation over 3 weeks 
(Figure 42A, B).  
 
Figure 42 : Influence of Huh7 differentiation on IMPs expression. Long term treatment (21 day) of Huh7 
with HS differentiate Huh7 toward the normal hepatocytes. Representative Western blot shows IMPs 
expression in Huh7 cells during HS treatment. The signal quantification of IMPs expression was 
normalized to the tubulin signal. The expression of IMPs after HS treatment (W1, W2, W3) was 
normalized to the control FCS treated Huh7 cells. P value was calculated either with ANOVA or Mann-
Whitney. Data represent mean ± SEM. N = 2 (triplicates). 
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2.4.3 In vivo biological activity of hit compounds 
A xenograft Zebrafish experiment was performed to investigate the potential in vivo 
biological activity for final hit compounds. Based on the collected data from the 
biophysical assays, biological assessment, on-target activity, and cytotoxicity to 
differentiated Huh7 cells, three compounds were selected for further in vivo 
assessment. Compound # 4, # 6 and # 9 were used in concentrations of 20 µM and 50 
µM. Zebrafish experiment was done by Charltotte Dahlem, the quantification of 
fluorescence signal with ImageJ software showed that compound # 4 and # 6 at 50 µM 
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Expression of IMPs in adult tissues has been described to be oncogenic in different 
types of tumors, including hepatocellular carcinoma (HCC), colon, and lung cancer 
(Dimitriadis et al., 2007; Kessler et al., 2016). IMP2 is highly expressed in different 
cancers compared to IMP1 and IMP3 (Dai et al., 2017; Kessler et al., 2017). Also, it 
has been reported that elevated IMP2 expression is associated with poor survival rate 
while that of IMP1 and IMP3, is not (Davidson et al., 2014; Kessler et al., 2017). IMP2 
and its variant p62 are involved in a higher extent compared to IMP1 and IMP3 with 
elevated RAC1 expression and generation of reactive oxygen species (Kessler et al., 
2017). Depletion of IMP1 reduced the migration of cancer cells, but did not affect 
cellular proliferation (Hsieh et al., 2013), data not available regarding to IMP3 knockout 
model.  
IMP2 knockout mediated by CRISPR/Cas9 approach reduced the proliferation rate in 
different cancer lines (Dai et al., 2017; Degrauwe et al., 2016). The overexpression of 
IMP2 enhanced the proliferation of cancer cells in a dose dependent pattern  to IGF2 
(Dai et al., 2017). P62 knockdown by RNAi decreased tumor growth and autophagy 
activation in the in vitro and xenograft model experiments (Ren et al., 2014). Our 
findings were in the same direction, the proliferation rate was reduced significantly after 
IMP2 knockdown/knockout. 
IMPs structure and function similarities might predict inter IMP family regulation 
(Conway et al., 2016; Nielsen et al., 1999). The reported mRNA binding sequences of 
IMP2 have been noticed frequently in IMP1 and IMP3 mRNAs. However, Dai and his 
colleges revealed that IMP2 knockout in mouse embryo fibroblasts did not alter both 
IMP1 and IMP3 expressions (Dai et al., 2017). Our findings predicted potential inter 
IMP regulation in cell type dependent pattern, even though the available literature 
regarding to inter IMP regulation is not sufficient to draw a consistent conclusion. 
 
Targeting RNA binding proteins is a promising approach in the treatment of different 
diseases (Ascher et al., 2014; Hong, 2017). NS5A is an RNA binding protein which is 
expressed in the HCV infected cells, and it is crucial for genome replication(Bell et al., 
2016). Daclatasvir and Elbasvir are FDA approved medications targeting NS5A , and 
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could successfully limit the growth of HCV and improved the therapy outcome (Bell et 
al., 2016). This information together with the knowledge on IMP2 oncofetal nature are 
important aspects interpreting why IMP2 represents a promising therapeutic target in 
cancer therapy. 
 
FP assay is a method that permit rapid, reliable and quantitative detection of protein 
ligand interactions and compound screening for the purpose of small molecule drug 
discovery (Burke et al., 2003; Lea and Simeonov, 2011). FP assay has been utilized 
in direct screening for enormous range of targets as DNA, RNA, protein (Bridges and 
Jennison, 1984).  
For IMP1 small molecule inhibitors were suggested using FP assay to inhibit IMP1 
RNA (AGAACAA) interaction (Mahapatra et al., 2017; Mahapatra et al., 2014). IMP1 
lead compound did not show any inhibitory effect on IMP2 interactions with either 
RNA_A or RNA_B. Hafner and colleges showed that RNA (ACACAA) is specific 
binding sequence for IMP2 (Hafner et al., 2010). FP assay results revealed some 
potential inhibitors for HuR/ELAVL1(RBP) interaction with adenine- and uridine-rich 
elements (ARE) in 3′UTR of target mRNAs, (Wu et al., 2015). Another RBP, MSI-1, 
has been shown via FP assay to be targeted by (-)-gossypol (Lan et al., 2015). LIN28, 
an RBP, interaction with Let-7 was inhibited with potential inhibitor discovered with 
protein/RNA-FRET approach (Roos et al., 2016).  
Our identified hit compounds with FP assay were initially synthesized as antibacterial 
agents and both compounds classes reported in Hinsberger et al. (2013) and  Sahner 
et al. (2013), they were designed as inhibitors of bacterial RNA polymerase enzyme 
(RNAP). The amino acid sequences and the architecture of bacterial RNAP differs 
fundamentally from the eukaryotic RNAP. No amino acid sequence similarities were 
found between either RNAP or IMP2. Furthermore, the Benzamidobenzoic acid 
derivatives (class A) are potent inhibitors for bacterial cell to cell communication system 
(Hinsberger et al., 2014). Pseudomonas quinolone signal communication system 
(PqsD) is a substrate for class A hit compounds.  
FP assay is a robust method that has low hit rate (0.1%) and minimal chance of false 
positive hits (Hall et al., 2016). However, false positive results reported in FP assay 
due aggregation and formation of missile like particles (Seidler et al., 2003; Shoichet, 
Discussion 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 60  
 
2006). As a result, further confirmation assays for the primary screening results 
generated by FP assay was recommended using different detection concepts (Bibette, 
2012; Sink et al., 2010). IMP2-hit compound interactions were confirmed by TSA, MST, 
STD-MNR, and molecular docking.   
In TSA, the increase in protein thermal stability is proportional to the affinity and 
concentration of ligand (Bai et al., 2019; Cimmperman et al., 2008). However, several 
studies reported that the bound ligands might destabilize proteins (Bernetti et al., 2017; 
Cimmperman et al., 2008). Some ligands destabilize the protein complex by enhancing 
protein refolding and this might reduce the fluorescence signal (Bai et al., 2019). 
Another explanation, ligand might bind selectively to the unfolded state of the protein, 
destabilize and reduce protein melting temperature (Cimmperman et al., 2008). Our 
TSA results showed that class A and B hit compounds destabilize IMP2 and reduce its 
melting temperature. In concordance to our findings, similar hits for LANA protein were 
reported to destabilize LANA complex and lead to reduction of melting temperature. 
(Kirsch et al., 2019).  
The IC50 value of compound # 9 measured by MST is relatively lower than what is 
reported in FP assays. MST assay performed in semi natural environment, and the 
protein itself is labeled instead of RNA as in FP assay (Seidel et al., 2013). This might 
be interpreted by the competitive interaction mode in FP assay but not in MST (Lea 
and Simeonov, 2011). Furthermore, recently Biswas and colleges revealed that the 
RNA (CGGA) interacts with IMP2 KH4 binding domain (Biswas et al., 2019). The 
reported RNA sequence was not included in either RNA_A or RNA_B.  
Several studies reported uses of STD-NMR in detection and confirmation of small 
molecules interaction with RNA / DNA binding proteins (Della Volpe et al., 2019; Kirsch 
et al., 2019). Furthermore, STD-NMR could provide a crucial insight into the ligand 
protein interactions and reveal the ligand active pharmacophores (Harris et al., 2013; 
Mayer and James, 2004; Vasile et al., 2018). Our STD-NMR findings showed that most 
of ligand epitopes are involved in the interaction with IMP2. This suggest the surface 
interaction that might require to inhibit IMP2 interactions with macromolecules as RNA. 
Our findings were in concordance with Kirsch and colleges findings for similar hits 
(Kirsch et al., 2019). Furthermore, STD-NMR produced a conclusive interaction pattern 
of optimized hits for LANA, and provided a robust approach for further structure 
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optimization and improvement (Kirsch et al., 2019). Our STD-NMR findings revealed 
inconsistent mode-of-interaction of hit compounds. This might result from different 
binding affinities of hit compounds to IMP2 RRM and KH binding domains. 
Furthermore, further STD-NMR experiments for other compounds optimized for IMP2 
might lead to provide a consistent mode-of-interaction.  
Virtual screening techniques have been used for identification of small molecule and 
lead optimization (Gohlke and Klebe, 2002). Usually, virtual screening is a preliminary 
screening approach, before starting with the traditional experimental screening assays 
(Bailey and Brown, 2001; Moitessier et al., 2008).  In the opposite direction, our 
molecular docking approach was set up to validate hit compounds binding and predict 
their interaction pose in the light of STD-NMR findings. In the same direction, STD-
NMR and docking studies revealed the interaction mode of HuR/ELAVL1 with small 
molecule inhibitors (Della Volpe et al., 2019; Vasile et al., 2018). Our findings revealed 
that all hit compounds in silico can inhibit different RNAs interaction (ACAC/CAC, 
CCCC, CGGA) with IMP2 (RRM1 and KH34 domains) in different affinities based on 
RNA and binding domain (data are not shown). 
The process of classical drug discovery relies on interactive cycles gathering medicinal 
chemistry and biological evaluation (Sliwoski et al., 2013). The chalenge in cancer 
therapy is to develop theraputic agents targeting specificaly the oncogenic factors 
responsible for the initiation and progression of cancers (Bhullar et al., 2018; Hoelder et al., 
2012).  
Validation of target specificity for a hit compound can be investigated based on lead 
potency on target expressing cells compared to target non-expressing cells (Hughes 
et al., 2011). The anti-proliferative activity of small molecule inhibitors targeting IMP1 
c-myc interaction was investigated using IMP1 expressing cells (IGROV-1) compared 
to IMP1 non-expressing cells (PC-3) (Mahapatra et al., 2017; Mahapatra et al., 2014). 
The natural product (-)-gossypol has been reported to inhibit MSI-1 and showed anti-
proliferative effect on colon cancerous cells compared to normal colon cells (Lan et al., 
2015). Our findings showed most of final hit compounds were biologically actives 
against different cancer cell lines. Furthermore, hit compounds showed the lowest 
potency on MCF7 cells compared to IMP2 expressing cells.  
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Assessment of compounds specificity via target gene knockout model is a robust approach 
compared to different cells comparison (Smith, 2003; Wyatt et al., 2011). The current study 
findings showed on-target biological activity of hit compounds compared to IMP2 
knockout/knockdown cells. 
Differentiated Huh7/7.5 cells might serve as suitable model for the cytotoxicity 
assessment of IMP2 inhibitors (Steenbergen et al., 2018). Class A compounds has 
affected the viability of differentiated and non-differentiated Huh7 cells. In addition to 
RNAP enzyme, class A hit compounds have broader spectrum as antibacterial 
compared to class B, since they interact with bacterial PqsR enzyme (Hinsberger et 
al., 2014; Hinsberger et al., 2013; Sahner et al., 2013). The multi-target activity of class 
A compounds might explain the reported higher toxicity in comparison to class B 
compounds. 
During Huh7/7.5 differentiation, 32% of genes were upregulated or downregulated 
indicating process of cell reprograming. The expression of genes encode CYP450 
enzymes is upregulated, cells resorted their secretory process (Petersen et al., 2017; 
Steenbergen et al., 2018). The noticed nontoxic effect in class B compounds might be 
associated with the elevated cell metabolism after upregulation of CYP450 enzymes 
(Petersen et al., 2017; Steenbergen et al., 2018). 
 
Recently, the use of the in vivo zebrafish model in drug discovery and drug toxicity 
assessment became a prominent model since zebrafish embryos are transparent and 
develop rapidly (Chakraborty et al., 2009). Our hit compounds showed in vivo inhibition 
of tumor growth in xenograft zebrafish model.  
Our findings regarding the generated hit compounds serve as a promising starting point 
for further optimization via structure activity relationship studies aiming to generate 
more potent and target-specific compounds. Furthermore, screening of additional 
libraries through the established biophysical methods and molecular docking in order 
to identify structure-divergent compound series. Screening for small molecules via 
IMP2 mediated CRISPR/cas9 HCT116 might serve as a robust biological screening 
approach.  
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4 Chemicals and reagents  
 
Kanamycin sulfate, cOmplete® protease inhibitor cocktail tablets, diethylpyrocarbonate 
(DEPC), isopropyl-β-D-thiogalactoside (IPTG), Pluronic®, lysozyme, bovine serum 
albumin (BSA), and salts were purchased from Sigma Aldrich (Darmstadt, Germany). 
Water was treated with 0.1% (v/v) DEPC in all experiments handling with RNA. 
Secondary antibodies utilized in immunodetection IRDye® 680RD goat anti-rabbit 
(#926-68071), and IRDye® 800 CW goat anti-mouse (#926-32210) were purchased 
from LI-COR Biosciences (Bad Homburg, Germany). The InstantBlue® Ultrafast 
Protein Stain solution was purchased from Sigma-Aldrich (# ISB1L, Darmstadt, 
Germany). The High Capacity cDNA Reverse Transcription Kit (#4368813), and 
RNase inhibitor RNaseOUT® (#10777019), were purchased from Thermo Fisher 




5.1 Cell culture  
SW480, HCT116, and MCF7 cells were maintained in DMEM, HepG2, Hep3B, Huh7, 
and Plc/Prf/5 cells in RPMI 1640 medium. Media were supplemented with 10% fetal 
bovine serum (FBS), 1 mM glutamine, 100 U/mL penicillin, and 100 µg/mL 
streptomycin. Cells were cultured at 37°C and 5% CO2. 
 
5.2 IMP2 siRNA knockdown  
A mixture of 4 different HPLC-purified double-stranded RNA oligonucleotides were 
used for IMP2 knockdown. Random siRNA was used as a control, the RNA 
oligonucleotides were purchased from Qiagen (Hilden, Germany). RNA oligo 
sequences are shown in Table 4.  
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Table 4:  siRNA oligonucleotide used in IMP2 knockdown. 
siRNA oligonucleotide Catalog no Sequence (5’ - 3’) 
oligo 1 SIO4367020 CCCGGGTAGATATCCATAGAA 
oligo 2 SIO4138820 CAGCGAAAGGATGGTCATCAT 
oligo 3 SIO3232481 TCCGCTAGCCAAGAACCTATA 
oligo 4 SIO3176593 CAGGGCGTTAAATTCACAGAT 
random 4390771 AACACGTCTATACGC 
 
IMP2 knockdown in Hep3B cells was performed in 96-well plates.  Forward transfection 
was done for SW480 (5,000 cells / well) and Hep3B cells (12,750 cells / well), and 
reverse transfection was used for Plc/Prf/5 cells (7,500 cells/ well). The siRNA 
concentration per well was 0.25 nM for SW480 and 1 nM for Hep3B and Plc/Prf/5 using 
INTERFERin® Polyplus-Transfection (Illkirch, France) transfection reagent to 0.75 µl / 
well as recommended by the manufacturer. Cell viability was measured via MTT assay 
72 h after transfection. 
5.3 IMP2 CRISPR mediated knockout 
CRISPR/Cas9 experiments were done by Tarek Kröhler. The CRISPR/Cas9 technique 
was adapted to disrupt the gene of human IMP2 in mammalian colon (SW480, 
HCT116) and liver cancer cell lines (HepG2, Huh7). The cells were transfected with a 
validated single guide (sg) RNA (TrueGuide® synthetic guide RNA, Thermo Fisher 
Scientific, Munich, Germany) targeting IMP2 (5’-GATGGACTTTTGGCTCAATA-3’) 
and a recombinant Cas9 protein (TrueCut®Cas9 Protein v2, #A36496, Thermo Fisher 
Scientific, Munich, Germany) using Lipofectamine® CRISPRMAX® Cas9 transfection 
reagent (#CMAX00001, Thermo Fisher Scientific, Munich, Germany) according to the 
manufacturer’s instructions. 80,000 cells were seeded in RPMI or DMEM media as 
described above, without antibiotics into a 12 well plate, incubated overnight, and 
transfected the next morning at a confluency of 30-70%. After 48 hours incubation time, 
the cells were detached, counted, and seeded into 96 well plates at a concentration of 
0.8 cells/well for limiting dilution cloning. The residual cells were used for gDNA 
extraction and further verification of editing efficiency via T7E1 mismatch assay. 
Surviving clones were cultured in 24 well plates and harvested for downstream 
experiments until knockout of IMP2 or at least reduced expression (monoallelic editing 
of the target region as assessed by Sanger sequencing) could be confirmed by 
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Western blot. Clones that showed reduced IMP2 expression in Western blots 
underwent the whole procedure again until knockout was achieved. At least two rounds 
of CRISPR/Cas9 editing did not induce a biallelic knockout in SW480 and Huh7 cells. 
Tarek kröhler participated in writing this part. 
5.4 Western blot 
Preparation of protein lysate was done in SB lysis buffer (50 mM Tris-HCl, 10% 
glycerol, 1% SDS, 5% β-mercaptoethanol, 0.004% bromophenol blue), in presence of 
a cOmplete® Mini protease inhibitor cocktail (#04693124001, Roche, Mannheim, 
Germany). Samples were stored overnight at -80°C to increase the efficacy of cell lysis, 
samples were aliquoted and stored at -20◦C.  
5.4.1 SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was done using polyacrylamide 
gels (4% collection gel and 12% separation gel) and the Mini PROTEAN system (Bio-
Rad, Munich, Germany).  Samples were thawed on ice and denatured at 95°C for 5 
min and gently centrifuged before loading into polyacrylamide gel.  A pre-stained 10 to 
180 kDa protein marker (#26616, Thermo Fisher Scientific, Mannheim, Germany) was 
run in parallel to the tested samples in each run to estimate protein masses.  Equal 
amount of tested proteins and an appropriate protein ladder volume were loaded onto 
the polyacrylamide gel and separated in electrophoresis (running) buffer (25 mM Tris, 
192 mM glycine, 0.1% SDS in final volume of 1 l distilled water) by electrophoresis at 
80 V for 20 min, then at 120 V for 2.5 h using the Mini-PROTEAN® system (Bio-Rad, 
Richmond, CA, USA). 
5.4.2 Blotting 
The separated samples were transferred onto an Immobilon®-FL polyvinylidene 
fluoride (PVDF) membrane (#IPFL00010, Merck, Darmstadt, Germany) using a Mini 
TransBlot® cell (Bio-Rad, Munich, Germany). The stuff used in gel sandwich 
preparation were equilibrated in blotting (transfer) buffer (25 mM Tris, 192 mM glycine, 
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20% methanol, 0.05% SDS in final volume of 1 l distilled water). The PVDF membrane 
were activated prior to blotting for 30 seconds in methanol. Blotting was performed in 
cold transfer buffer at 80 mA overnight. The membrane was blocked in Rockland 
blocking buffer (RBB) (#MB-070, Rockland Immunochemicals, Limerick, PA, USA) for 
1 h to render the antibodies unspecific binding.  
5.4.3 Near infrared immunodetection  
Different antibodies were used in the immunodetection, they were diluted in RBB 
according to Table 5.  
 





anti-human IMP1, mouse 
IgG 






1:1,000 in RBB 
Lu et al. 
(2001) 
in house 
anti-human IMP3, rabbit 
IgG 
1:1,000 in RBB 12750-1-AP 
Proteintech, St. 
Leon-Rot, Germany 
















The membranes were incubated with anti-human IMP2 or IMP3 antibodies for 3 h at 
RT, and with anti-human IMP1 antibody overnight at 4°C. After incubation, the 
membranes were washed 4 times with PBST (0.1% Tween-20 (v/v) in 1 x PBS (10 mM 
Na2HPO4, 1.8 mM KH2PO4,137 mM NaCl, 2.7 mM KCl, pH 7.4)) (each time for 5 min 
on shaker), followed by incubation with anti-α-tubulin antibody for 1 - 1.5 h at RT. 
Afterward, the membranes were washed (4 x, 5 min) with PBST, followed by incubation 
with mixture of IRDye®680 and IRDye®800 conjugated secondary antibodies for 1-2 h 
at RT. The membranes were washed prior to detection with PBST (3 x, 5 min), and 
PBS (2 x, 5 min). Signal intensities were determined by using the Odyssey near-
infrared imaging system from LI-COR Bioscience (Bad Homburg, Germany). Western 
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blot signal intensities were quantified by Studio lite software (LI-COR Bioscience, Bad 
Homburg, Germany).   
 
5.5 Cytotoxicity and anti-proliferative measurement 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
used to measure the cell viability after IMP2 knockdown/knockout or treatment with hit 
compounds. Cells were seeded at different densities in 96 well plates based on the 
cells type and incubation time. Control cells were either non-treated or treated cells 
with the respective vehicle concentration according to the experiment set up. At the 
time of measurement, the medium was aspirated, and cells were incubated with 
prewarmed MTT solution (0.5 mg/ml in suitable medium) for 0.15 - 1 h at 37◦C. Then, 
MTT solution was aspirated and cells were lysed by 100 µl of DMSO (100%). The 
absorbance was measured at wavelength of 550 nm and reference wavelength at 690 
nm in a microplate reader (XFluor4 Sunrise®, TECAN, Promega, Madison, WI, USA).  
 
5.6 Gene expression analysis 
The human RNA from cultured cells was extracted with the High Pure RNA Isolation 
Kit 
(#11828665001, Roche, Mannheim, Germany), according to the manufacturer’s 
instructions. Total RNA concentration was measured at 260 nm and purity was 
controlled by 260/280 ratio with the Thermo Scientific® NanoDrop Lite 
Spectrophotometer (Wilmington, DE, USA). 
Reverse transcription of RNA and cDNA synthesis was performed with 300 ng total 
RNA per sample using the High Capacity cDNA Reverse Transcription Kit (#4368813, 
Thermo Fisher Scientific, Darmstadt, Germany), and RNase inhibitor RNaseOUT® 
(#10777019, Thermo Fisher Scientific, Darmstadt, Germany), according to the 
manufacturer’s instructions. Gene expression was analyzed using 5xHotFirePol 
EvaGreen qPCR Mix (#08-25-00020, Solis BioDyne, Tartu, Estonia) on a CFX96 
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touch® Real-Time PCR detection system running the CFX Manager 
2.1 software (Bio-Rad Laboratories, Munich, Germany).  
 
 RT-qPCR efficiency was checked for each run to be in an accepted range of 90 - 
105%. In general, Ct values were normalized to the housekeeping gene β-actin (ACTB) 
or 18S. Primers for IMP1, IMP2, and IMP3 genes, as well as the reference genes 
(ACTB of 18S) were purchased from Eurofins Genomics (Ebersberg, Germany). The 
used conditions in set up of qPCR reaction are summarized in Table 6. 
Table 6 : Conditions used in set up of qPCR reaction. 
Gene 
Forward primer sequence  
5´-3´ 
Reverse primer sequence 
5´-3´ 
µl primer 




IMP1 AGATAGACGTGCATAGGAAG GTGTCCTTAGCCTCTTTATG 0.5 62 
IMP2 CATATACAACCCGGAAAGAAC CTCTGGATAAGAGTGATGATG 0.4 62 
IMP3 GGAGGAGATCATGAAGAAAATC TTTCTGATTGCTCAAACTGC 0.4 62 
ACTB GACGACATGGAGAAAATCTG ATGATCTGGGTCATCTTCTC 0.4 60 
18S AGGTCTGTGATGCCCTTAGA GAATGGGGTTCAACGGGTTA 0.5 61 
 
A total volume of 20 µl per PCR reaction was used, all samples were performed in 
biological duplicates and technical triplicates within the PCR runs using the following 
program:  
denaturation 95°C 15 min 
denaturation 95°C 0.15 min 
35 cycles annealing °C*  0.20 min 
elongation 72°C 0.20 min 
final elongation 72°C 10 min  
Melting curve    
 65°C 
0.5°C / 5s 
 
 95°C  
 
* Annealing temperatures for each gene was adjusted based on Table 6.  
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5.7 Bacterial culture 
Different E. coli strains were used either for plasmid amplification or protein expression. 
The E. coli DH5α strain (Invitrogen, Carlsbad, CA, USA) was utilized as a host 
organism for plasmid amplification. The Bl-21 and Rosetta® (DE3) E. coli strains 
(Invitrogen, Carlsbad, CA, USA) were utilized as host organisms for recombinant 
proteins expression. Bactria were cultured and grown in lysogeny broth (LB) medium 
(10% Nacl, 10% tryptone, 5% yeast extract in dd water, pH 7.4), in presence or 
absence of kanamycin as a selection marker (50 µg/ml, Sigma-Aldrich). Agar plates 
(LB kan) were prepared by addition of 7.5 g agar-agar to 500 ml of the LB medium in 
presence of kanamycin. 
5.7.1 Generation to competent cells 
Calcium chloride (chemical) method was used in generation of competent E. coli.  A 
total volume of 5 ml from overnight culture was used to inoculate 100 ml LB medium 
without kanamycin. The bacterial culture was grown at 37°C with shaking until the 
OD600 reaches 0.4, then culture was placed on ice for 30 minutes. The cooled culture 
was centrifuged at 2,000 x g and resuspended in 10 ml cold CaCl2 solution and 
incubated on ice for another 30 minutes. Cells were collected by centrifugation at 2,000 
x g and resuspended in 2.5 ml cold CaCl2, aliquoted in 100 µl volume, and stored at -
80°C. 
5.7.2 Plasmid transformation  
The plasmid transformation onto bacteria was done by heat shock method. A total of 
2 ng vector was added to 100 µl competent cells. The mixture was incubated on ice 
for 20 min, then heated at 42°C for 2 min and incubated again on ice for 2 min. A total 
of 900 µl of prewarmed LB medium was added and the mixture was grown at 37°C 
with shaking for 1-2 h.  A total of 100 µl culture was spread in kanamycin agar plates 
and incubated overnight at 37°C. 
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5.7.3 Plasmid isolation  
Plasmid extraction was done from overnight culture using either High Pure Plasmid 
Isolation Kit (#11754777001, Roche, Mannheim, Germany), or NucleoSpin Plasmid 
(NoLid), Mini kit (#740499.50, Macherey-Nagel, Düren, Germany), according to the 
manufacturer’s instructions. Plasmid DNA concentration was measured at 260 nm and 
purity was controlled by 260/280 ratio of with the Thermo Scientific® NanoDrop Lite 
Spectrophotometer (Wilmington, DE, USA). 
 
5.8 Protein purification 
5.8.1 IMP2 expression 
Histidine-tagged full-length IMP2 was expressed using a pET-28a vector in BL-21 E. 
coli at 18° C; expression was induced with 0.4 mM IPTG. Cells were harvested by 
centrifugation at 6,733 × g and resuspended in binding buffer (20 mM Tris–HCl, pH 
7.4, 2 mM MgCl2, 150 mM NaCl, 10 % glycerol (v/v), 2 mM mercaptoethanol, 40 mM 
imidazole). EDTA-free protease inhibitor cocktail (cOmplete®, #11836170001, Sigma-
Aldrich, Darmstadt, Germany) was added freshly to the binding buffer. Cells were lysed 
using a French press homogenizer (two passages) and cell debris were removed by 
centrifugation at 42,858 × g at 4°C for 1 h. 
5.8.2 Immobilized metal affinity chromatography 
The supernatant was applied to a 5 ml HisTrap HP Nickel–Sepharose column 
(#17524701, GE Healthcare Life Sciences, Frankfurt, Germany) at 0.75 ml/min on an 
ÄKTAxpress system (GE Healthcare). The column was equilibrated with binding buffer 
in 10 x column volume or until the UV signal was stable. The column was then washed 
with 15 x column volume with binding buffer and with 15 x column volumes of high salt 
at 3 ml/min. (Tris–HCl, pH 7.4, 2 mM MgCl2, 1 M NaCl, 2.5% glycerol (v/v), 2 mM 
mercaptoethanol, 40 mM imidazole). Subsequently, the column was washed with 15 x 
column volumes of binding buffer containing 100 mM imidazole.   
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Then a gradient washing was done with a linear gradient to 100% of 500 mM imidazole 
buffer (Tris–HCl, pH 7.4, 2 mM MgCl2, 150 mM NaCl, 2.5% glycerol (v/v), 2 mM 
mercaptoethanol, 500 mM imidazole) in 10 x column volumes at 3 ml/min.  
The protein was eluted in 0.7–1 M imidazole buffer (Tris–HCl, pH 7.4, 2 mM MgCl2, 
150 mM NaCl, 2.5% glycerol (v/v), 2 mM mercaptoethanol, 700-1,000 mM imidazole), 
protein purity and identity were assessed by SDS-PAGE, Western blot, and circular 
dichroism spectrometry (CDS). The eluted IMP2 fractions were concentrated via 
centrifugal filtration using Vivaspin columns (30,000 MWCO, # VS0121, Sartorius, 
Gottingen, Germany). Buffer exchange into storage buffer (Tris–HCl, pH 7.4, 2 mM 
MgCl2, 150 mM NaCl, 2 mM DTT, 10% glycerol (v/v), in DEPC treated H2O) was 
performed using multi-step dilution inside Vivaspin columns. Protein concentrations 
were measured by both UV spectroscopy (ε=280 nm) and Pierce assay (according to 
the manufacturer’s instructions). Protein aliquots were stored at -80°C. 
5.8.3 Recombinant IMP2 visualization 
The collected protein fractions during IMP2 isolation were subjected into SDS-PAGE 
as mentioned in 2.3.1. A loading buffer (4 x Roti®-Load 1, #K929.1, Carl-Roth, 
Karlsruhe, Germany) was added to the recombinant protein samples before 
denaturation. The separated protein samples were incubated ON in InstantBlue® 
Ultrafast Protein Stain solution (# ISB1L, Sigma-Aldrich, Darmstadt, Germany). Gels 
were scanned using the Odyssey near-infrared imaging system from LI-COR 
Bioscience (Bad Homburg, Germany).  
5.8.4 RNA electrophoresis 
The absence of potential RNase contamination in the protein preparations was 
assessed by mixing 15 µl of human RNA (470 ng/µl) isolated from MCF7 cells with 
either 15 µl storage buffer or 15 µl IMP2 protein (22.1 µM) and incubated on ice or at 
RT for 1.5 h. RNA electrophoresis was performed in presence of 2.2M formaldehyde 
to achieve full RNA denaturation as described in Maniatis et al., (1982). A total of 1% 
agarose gel was prepared by melting 0.5 g agarose in 37 ml distilled water, cooled to 
approximately 55°C and mixed with 8.75 ml 40% formaldehyde and 5 ml 10 x 
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autoclaved MOPS (0.2M MOPS pH 7.0, 50 mM sodium acetate, 5mM EDTA). A total 
of 5 µl 10 mg/ml ethidium bromide was added for RNA visualization. RNA samples 
were mixed with 4 x denaturation buffer (10 ml 100% deionized formamide, 3.5 ml 40% 
formaldehyde, 1.5 ml 10 x MOPS buffer) before subjection into the agarose gel. RNA 
samples were separated at 100 V. A 1 kbp ladder (#11823963, Thermo Fisher 
Scientific, Darmstadt, Germany) was run parallel to the RNA samples for size 
determination. RNA visualization was performed using a UV transilluminator (Biostep 
Dark Hood DH-40/50) and the software ArgusX1 (Biostep, Jahnsdorf, Germany). 
5.8.5 Liquid chromatography – tandem mass spectrometry 
The liquid chromatography– tandem mass spectrometry was done by Dr. David 
Aurabach (Department of Microbial Natural Products, Helmholtz Institute for 
Pharmaceutical Research Saarland (HIPS), Saarland University, 66123 Saarbrücken, 
Germany). 
5.9 Fluorescence polarization-based screening assay 
5.9.1 Probe design 
Fluorescein (FLC) labeled or non-labeled HPLC-purified single-stranded RNA 
oligomers were purchased from Sigma-Aldrich (Darmstadt, Germany). Based on 
published IMP2 target sequences, two different RNA oligonucleotides were designed 
as IMP2 binding partners. The sequence of RNA_A was based on the published motifs 
CAUC, ACACA, and CCCC (Conway et al., 2016; Hafner et al., 2010; Jia et al., 2018) 
and contained a 3’ nucleotide extension after the FLC label: FLC-
AUGCAUCCCCGCAGCUACACACACACAACA. RNA_B was designed based on the 
binding motif UUCACGUUCAC described by (Nielsen et al., 1999) and contained the 
motif as a tandem repeat with a 7-nucleotide extension before FLC: 
CCCCCCUUUCACGUUCACUCUGUCU-FLC. A third RNA_C sequence (FLC-
GAAAAAAAGAUUUAUUUAUUUAAGA) was reported to bind to AU rich elements 
(ARE) building proteins and was used to detect the specificity of the fluorescent probe 
binding to the target (Wu et al., 2015). 
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5.9.2 Compound libraries 
A total number of 1,428 compounds from four different libraries was screened ; ( 838 
compounds were from a synthetic in house library from the Helmholtz Institute for 
Pharmaceutical Research Saarland (HIPS), 253 compounds from in the house natural 
products library from HIPS, 192 compounds from ASINEX (Winston-Salem, NC, USA; 
https://www.asinex.com/), and 145 compounds from the Maybridge library (small 
molecular weight chemical fragments, Thermo Fischer Scientific®: 
https://www.maybridge.com/portal/alias__Rainbow/lang__en/tabID__177/DesktopDef
ault.aspx. Compounds were dissolved in DMSO to a concentration of 5 or 10 mM 
stocks depending on their solubility.  
5.9.3 FP assay optimization and validation 
FP and fluorescence intensity (FI) were measured using a CLARIOstar® Plus 
microplate reader (BMG LABTECH, Ortenberg, Germany) with an excitation at 485-
495 nm and an emission at 520-530 nm. In general, focal height and gain adjustments 
were done before starting each measurement to reach the maximum sensitivity (Rossi 
and Taylor, 2011). The FI values of any compound deviating more than ± 20% from 
values of the controls were excluded from further procedure (Nakayama et al., 2006). 
Each sample was tested in duplicate, and FP values are reported in milli polarization 
units (mP). Lyophilized RNA oligomers were dissolved in FP assay buffer (Tris–HCl, 
pH 7.4, 2 mM MgCl2, 150 mM NaCl, 10% glycerol, 2 mM DTT, 10% glycerol (v/v), in 
DEPC treated H2O), to have 100 µM stock solutions of RNAs, further diluted into 100 
nM aliquots, and stored at -80°C. Saturation experiments were performed to detect 
direct binding of different RNA oligomers to either IMP2 or BSA. Thereby, a constant 
concentration (1 nM final) of each FLC-labeled RNA with a constant concentration (1 
nM) were titrated with serial dilutions in a range of 0.15 nM to 3 µM final concentration 
in FP assay buffer. In the competitive FP experiments, IMP2 was used in excess (2-3 
folds above the EC50 values). Based on the saturation experiments, a final IMP2 
concentration of 200 nM was selected to be used in subsequent competition assays 
with RNA_A and RNA_B. 
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All competitive experiments included a 1-hour incubation of IMP2 with nonlabelled 
RNA oligo or compounds in black 384 well microplates before the addition of the 
labeled RNAs. Competition experiments were done at constant concentrations of 
RNA_A and RNA_B (1 nM) and a fixed IMP2 concentration (200 nM) by titration 
against serial dilutions of unlabeled RNAs (0.32 nM-100 µM final). DMSO tolerance 
was evaluated by incubating different DMSO concentrations (0 –10% v/v) and RNA_A 
or RNA_B at 1 nM, either with or without IMP2. The stability of FP values was assessed 
over time by measuring the FP at different time points (every 30 min until 4 h). The 
assay robustness was verified by assaying low controls (LCs) in 192 samples with 
RNA_A or RNA_B (1 nM final concentration) in 5% DMSO in FP assay buffer and a 
high control (LC) plate containing the 192 samples in the same plate in addition to 
IMP2. Z’ value was calculated according to the formula Z’ = 1 – [(3SD * HC) + (3SD* 
LC)] / ǀ(HC mean - LC mean) (Zhang et al., 1999).  
5.9.4 FP-based screening 
Compounds were diluted in FP assay buffer to concentrations of 450 µM. A total of 10 
µl in duplicates (15% DMSO) from each compound was added into 384 well microtiter 
plates using an electronic Eppendorf Xplorer® 12-channel pipette (Eppendorf, 
Germany). In addition, 10 µl of 600 nM IMP2 in FP assay buffer was added into the 
same plate, and the samples were incubated for 1 h shaking at room temperature. 
Afterward, 10 µl of a 3 nM RNA_A/B solution in FP assay buffer was added to the 
mixture and incubated for an additional 1.5 h at room temperature in the dark. 
Accordingly, the final assay concentrations were 1 nM of RNA_A/B, 200 nM of IMP2, 
and 150 µM for compounds, in 5% DMSO. Any compound that enhanced or quenched 
the total FI more than 20% of the FI of the controls was excluded. The percentage of 
binding inhibition was calculated as: % inhibition = (mean of HC – read compound 
value) / (mean of HCs – mean of LC) × 100%. In addition, Pluronic® was added to the 
FP buffer to a final concentration of 0.01% in the competitive assay to rule out any 
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5.9.5 FP-based dose-response measurement 
Different dilutions of a 333 µM starting concentration of hit compounds were prepared 
in FP buffer in 5% DMSO and titrated in the presence or absence of IMP2. The 
experiments were performed in two independent experiments using duplicates.  
 Compound solubility test 
The solubility limit of hit compounds was tested qualitatively by sight inside a 
transparent glass vial and quantitively by measuring the absorbance at 620 nm. The 
cut limit was determined by the up surging of absorbance value compared to the 
control.  
  
5.10 Thermal shift assay 
The shift of the melting point of IMP2 in the presence or absence of hit compounds 
was recorded in 96 well plates using an Applied Biosystems® StepOnePlus® Real-Time 
PCR System from Thermo Fisher Scientific (Darmstadt, Germany). Thermal shift 
experiments were performed at fixed concentrations of IMP2 (4.5 µM), and 100 µM hit 
compound. Sypro Orange dye (Sigma Aldrich, Darmstadt, Germany) was used in 2.5-
fold concentration (stock 5,000-fold) in a total volume of 20 µl. The heating gradient 
started at 25ºC, and the temperature was increased by 0.5°C/ min to 95°C, detecting 
the fluorescence of Sypro Orange. Melting curve plots of fluorescence versus 
temperature were converted into melting peaks and melting temperatures were 
calculated subsequently by Protein Thermal Shift Software v1.3-Thermo Fisher 
Scientific (Darmstadt, Germany).  
5.11 Microscale thermophoresis technique 
His6-IMP2 protein was diluted to 600 nM in MST buffer (20 mM Tris-HCl, pH 7.4, 
150mM NaCl, 0.01% Pluronic®, 0.5% Tween-20, 10% glycerol). Monolith His-Tag 
Labeling Kit purchased from NanoTemper Technologies GmbH® (Munich, Germany), 
RED-tris-NTA dye was diluted in MST buffer to a final concentration of 100 nM. 100 µl 
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of IMP2 was mixed with 100 µl of NTA dye and the mixtures were incubated for 30-60 
min at room temperature in the dark. 
12-step serial dilutions (500 µM to 15 nM) of hit compound # 9 were prepared in MST 
buffer with 5% DMSO, with a final volume of 10 µl in each 1.5 ml tube of the dilution 
series. 10 µl of 600 nM His6-labeled IMP2 protein was added to each sample and 
mixed by pipetting up and down. Reaction mixtures were incubated for 1 h at room 
temperature in the dark and then were loaded into Monolith NT.115 capillaries. MST 
was measured using the Monolith NT.115 Microscale Thermophoresis Instrument from 
NanoTemper Technologies (Munich, Germany). 
5.12 Saturation transfer difference – NMR 
1H–STD-NMR experiments were conducted using a Bruker Fourier spectrometer 
(500 MHz), (Massachusetts, USA), and the probe temperature was kept at 283 K. 
The final compound concentration was 250 or 500 µM based on the solubility limit in 
10% DMSO D6. A volume of 25 µl from each compound solution was diluted with 25 
µl of Tris buffer pH 7.4, 150 mM NaCl in D2O. IMP2 protein/ligand was used in 1:100 
ratio with a final concentration of 2.5 or 5 µM, respectively. A control spectrum was 
recorded under the same conditions without a protein to test for artifacts. 
The STD-NMR experiments were carried out with a carrier set at -1 ppm for the on-
resonance and -40 ppm for the off-resonance irradiation. Selective IMP2 protein pre-
saturation was carried out at 0.5 s by using a train of 50 ms Gauss-shaped pulses. The 
mentioned NMR conditions were established and optimized by Dr. Josef Zapp. 
The STD effect resulting from the difference in signal intensity after saturation transfer 
was quantified using formula STDeffect = (I0 - Isat)/I0. This provides insights into the 
relative proximity of the respective protons to the protein surface. I0 represents the 
intensity of one signal in the off-resonance or reference spectrum, and Isat represents 
the intensity of a signal in the on-resonance spectrum. 
The STD-NMR spectrum of the IMP2 : ligand sample was subtracted from the 
respective STD spectrum of the ligand alone using the same NMR conditions to 
eliminate any artefacts arising from the ligand. Protons of the residual imidazole 
contamination from the elution step appear at 7.2 and 8.1 ppm.  
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5.13 Molecular docking 
The homology modelling and molecular docking experiments were performed with 
MOE 2019.01 (Molecular Operating Environment). A homology model for IMP2 RRM1 
was generated using a reported NMR structure of IMP2 (RRM1, pdb ID: 2CQH) 
(Suzuki et al., 2005) and an X-ray structure of IMP3 in complex with RNAs (ACAC and 
CCCC) (IMP3 RRM12, pdb ID: 6GX6 and 6FQR) (Jia et al., 2018). Another homology 
model for IMP2 KH34 was generated using a reported X-ray structure for IMP2 (KH34, 
pdb: 6ROL) (Biswas et al., 2019) and an X-ray structure for IMP1 in complex with RNAs 
(CAC/CCC, and CGGA) , (KH34, pdb ID: 2N8L and 2N8M, respectively) (Nicastro et 
al., 2017). 
The sequence of IMP2 RRM1 and KH34 as well as the co-crystalized RNA structures 
atom coordinates were loaded into MOE and the homology model was generated using 
the built-in homology model function with standard parameters, AMBER10:EHT force 
field, and the RNA atoms as environment. Dr. Martin Empting was participated in 
docking of compound 4 with RNAs (ACAC). 
 
5.14 Biological activity of hit compounds on cell viability and proliferation 
Cells were seeded in 96-well plates at a density of 2,500 -10,000 cells/well based on 
cells type (95-100% confluency at time of measurement). Cell viability was measured 
96 h after treatment of hit compounds at the indicated concentrations (80, 70, 60, 50, 
40, 30, 25, 20, 15, 12.5, 10, 5, and 1 µM) using MTT. For each compound, the inhibition 
of cell proliferation was calculated for each concentration relatively to their respective 
DMSO control or non-treated control for the viability above 90%. IC50 values were 
calculated with Origin pro version 19 software. The IC50 values are shown as a dot plot 
figure generated by Python 3.8.1 software. 
5.15 Electric cell-substrate impedance sensing 
ECIS represents a powerful tool to assess cell proliferation in real-time, but cell 
impedance is also responsive towards changes in cell adhesion (Stolwijk and 
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Wegener, 2019), which has been shown to be affected by IMP2 (Xing et al., 2019). 
HCT116 parental and IMP2 CRISPR knockout cells were seeded (7,000 cells/well in 
150 µl) into 96 (96W10E+) well plates coated with rat tail collagen (30 µg/ml in 0.2% 
acetic acid). The cells were seeded directly after the compounds were added into the 
plate to reduce cell stress. Cells were treated with 25 µM of hit compounds in triplicate. 
Effects of hit compounds on proliferation were normalized to (0.25%) DMSO controls. 
Cell impedance was assessed in an ECIS® Zθ (theta) instrument (Applied BioPhysics 
Inc., New York, USA). Measurements were started immediately after cell seeding and 
were taken every 450-900 s for each well. 
 
5.16 Proliferation of primary human umbilical vein endothelial cell 
HUVEC cells (50,000 cells in 100 µl medium per well) were cultured on 96 well plate 
and were treated with different hit compounds in final concentration of 25 µM and 50 
µM in 200 µl total volume. Cell viability was measured with MTT 72 h after incubation 
with hit compounds. 
 
5.17 Differentiation of Huh7 cells 
Huh7 cells were seeded into 96 well plates (3,000 cells/well) in full RPMI growth 
medium containing 10% FBS. After 24 h medium was aspirated and changed to RPMI 
medium containing 2% human serum (HS) in order to induce cell differentiation as 
described (Steenbergen et al., 2018). Fresh medium was added twice a week for 21 
days. Differentiated cells were treated with hit compounds, and cell viability was 
assessed with MTT assay 96 h after treatment. 
 
5.18 In vivo xenograft zebrafish embryo model 
The in vivo assessment of hit compounds 4, 6, and 9 on zebrafish was performed by 
Charlotte Dahlem as reported in (Dahlem et al., 2020). 
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5.19 Statistics 
Data analysis was done by Microsoft Excel, and statistics were performed using 
OriginPro 2019 b (OriginLab Corporation, USA). IC50 and EC50 values were calculated 
using non-linear regression analysis with Origin pro version 2019 software. Values are 
expressed as mean ± SD/SEM. Shapiro-Wilk test was performed to analyze data 
distribution. Depending on whether the data were normally distributed and on group 
size, statistical differences were calculated using a one-way ANOVA, Student`s t-test, 
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Summary and conclusion 
 
IMP2 protein is a promising target in cancer therapy. In this study, we showed that 
IMP2 knockdown/knockout slow down the proliferation rate of cancer cells. IMP1 and 
IMP3 expression are suggested to be targeted by IMP2 in cell dependent pattern.  
 
We showed for the first time that IMP2 is druggable, and IMP2 binding to its targets 
can be inhibited by small molecule compounds. For this purpose, a competitive FP 
assay was established. In the same context, TSA and MST were established as a 
secondary confirmation of FP assay findings.   
 
Furthermore, this study provides first insight into the mode-of-action of these inhibitors 
via STD-NMR orthogonal method and molecular modeling.  
 
The biological activity of hit compounds was assessed in different cancer cell lines and 
most of hit compounds were biologically actives. Further assessments showed hit 
compounds led to a target-specific reduction of cellular proliferation. Also, the toxicity 
studies showed class B compounds are nontoxic to normally proliferating cells.  
 
Furthermore, this study provides for the first-time an in vivo inhibition of tumor growth 
in xenograft zebrafish model via IMP2 inhibitors.  
 
This study serves as a promising starting point for further structure optimization via 
establishing structure activity relationship studies and pharmacophore modeling in 
order to identify more potent, and target-specific compounds. 
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supplementary data  
 
Supplementary data: Table 1. Descriptive data of class A. Table 1 shows the molecular weights, 
chemical structures, and analytical data of class A compounds. Abbreviations: carbonNMR (13C NMR); 
coupling constant (J); deuterated dimethyl sulfoxide (DMSO.d6); doublet peak (d); liquid 
chromatography–mass spectrometry (LC/MS); melting point (mp); multiplet peak (m); parts per million 
(ppm); proton NMR (1H NMR); quartet peak (q); retention time (tR); singlet peak (s); triplet peak (t). 
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Supplementary data: Table 2. Descriptive data of class B. Table 1 shows the molecular weights, 
chemical structures, and analytical data of class B compounds. Abbreviations: carbonNMR (13C NMR); 
coupling constant (J); deuterated dimethyl sulfoxide (DMSO.d6); doublet peak (d); liquid 
chromatography–mass spectrometry (LC/MS); melting point (mp); multiplet peak (m); parts per million 
(ppm); proton NMR (1H NMR); quartet peak (q); retention time (tR); singlet peak (s); triplet peak (t). 
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Supplementary data: Figure 1. STD-NMR IMP2 complex analysis. Further confirmation and characterization of 
IMP2-hit compound interactions was done using STD-NMR. The STD-NMR experiments were performed at fixed 
concentrations of 2.5-5 µM IMP2 and either 250 µM for compound 2 and 3 or 500 µM for compounds 5-6 and 13-
14 based on the solubility limit in 10% DMSO D6 (molar ratio of protein to ligand was 1:100). Compounds 2 and 3 
represent class A hit compounds (A), compounds 5 and 6 class B compounds (B), and compounds 13 and 14, 
selective RNA_A inhibitors (C). The reference spectrum without protein is shown in red, and the STD difference 
spectrum of the IMP2/compound complexes is shown in green. Overlaid STD off-resonance and STD effect spectra 
were normalized to the signal of the highest proton signal. 
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Supplementary data: Figure 2. DMSO concentration vs mean cell viability. Cell tolerance to different DMSO% 
was assessed in different cell lines used in the evaluation of the biological activity of hit compounds. Cell viability 
was tested with MTT 96 h after treatment with different DMSO concentrations (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 
0.8, 1, 2.5, 5%). Viability was normalized to non-treated controls. Data represent means ± SEM; n = 5 (at least in 
triplicates). 
Supplementary Data 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  




Supplementary data: Figure 3. DMSO concentration vs median cell viability. Cell tolerance to different DMSO% 
was assessed in different cell lines used in the evaluation of the biological activity of hit compounds. Cell viability 
was tested with MTT 96 h after treatment with different DMSO concentrations (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 
0.8, 1, 2.5, 5%). Viability was normalized to non-treated controls. N = 5 (at least in triplicates).  
 
Supplementary Data 
ــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 87  
 
 
Supplementary data: Figure 4. Effect of hit compounds on cell proliferation in the absence of the target. 
Cell impedance was assessed as readout parameter for cell density and adhesion. HCT116 parental 
and IMP2 CRISPR/Cas9 knockout cells were seeded in equal numbers and treated with 25 µM of the 
respective compound or DMSO solvent control (Co). Hit compounds demonstrated effective anti-
proliferative effects in HCT116 parental cells but (A) no or (B) lower effects in IMP2 CRISPR cells. Data 
are represented as means ± SEM; n = 2 (triplicates). 
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